A Single -Arm, Open -Label Phase 2 Pi[INVESTIGATOR_636623] (CPX -351) in Adults with 
Relapsed or Refractory Acute Lymphoblastic Leukemia  
[STUDY_ID_REMOVED]  
Version  3.0 
December 11, 20 19 
 
A Single- Arm, Open -Label Phase 2 Pi[INVESTIGATOR_636623] (CPX -351) in 
Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia.  
Protocol  Identifying  Number:  [ZIP_CODE]  
Principal  Investigator:  [INVESTIGATOR_636624], MD  
 IND/IDE  Sponsor:  Bijal Shah, MD 
IND Number: 138773  
Funded by:  
[CONTACT_156239], Inc.  
Version Number:   v.1.0 
25 January 2018 
 
Version Number: v.1. 1 
21 Feb 2018 
Vers ion Number: v.1.2 
30 Mar 2018 
Version Number: v.1.3 
20 Apr  2018 
Version Number: 2.[ADDRESS_851108] OF ABBREVIATIONS  .......................................................................................................vi  
STATEMENT OF COMPLIANCE  .............................................................................................vii  
STUDY  SUMMARY  ................................................................................................................. viii 
SCHEMATIC OF STUDY DESIGN  ............................................... Error! Bookmark not defined.  
1 KEY ROLES ............................................................................................................... 1  
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  1 
2.1 BACKGROUND INFORMATION  .............................................................................. 1  
2.2 RATIONALE  ................................................................................................................ 2  
2.3 POTENTIAL  RISKS AND BENEFITS  ....................................................................... 3  
2.3.1  KNOWN POTENTIAL RISKS ................................................................................ 3  
2.3.2 KNOWN  POTENTIAL  BENEFITS  ........................................................................ 4  
3 OBJECTIVES AND  PURPOSE  ................................................................................ 4  
4 STUDY  DESIGN  AND  ENDPOINTS  ....................................................................... 5  
4.1 DESCRIPTION OF THE  STUDY  DESIGN  ............................................................... 5  
4.2.1 PRIMARY  ENDPOINT  .......................................................................................... 5  
4.2.2 SECONDARY  ENDPOINTS  ................................................................................. 5  
4.2.3 EXPLORATORY  ENDPOINTS  ............................................................................. 5  
5 STUDY ENROLLMENT  AND  WITHDRAWAL  ......................................................... 6  
5.1 PARTICIPANT  INCLUSION CRITERIA  ................................................................... ...  6 
5.2 PARTICIPANT  EXCLUSION CRITERIA  .....................................................................  6 
5.3 STRATEGIES FOR  RECRUITMENT  AND  RETENTION ........................................ 7  
5.4 PARTICIPANT  WITHDRAWAL  OR TERMINATION .................................................. 8  
5.4.1  REASONS FOR  WITHDRAWAL  OR TERMINATION  ..................................... 8  
5.4.2 HANDLING  OF PARTICIPANT  WITHDRAWALS  OR TERMINATION  .............. 8  
5.5 PREMATURE  TERMINATION  OR SUSPENSION OF STUDY  ................................ 9  
6 STUDY  AGENT  .......................................................................................................... 9  
6.1 STUDY  AGENT(S)  AND  CONTROL  DESCRIPTION  ............................................... [ADDRESS_851109] STORAGE AND STABILITY  ...................................10 
6.1.5 DOSING  AND  ADMINISTRATION & ROUTE OF ADMINISTRATION  ...............10 
6.1.7  STARTING  DOSE  AND  DOSE ESCALATION  SCHEDULE  .........................10 
6.1.8 DOSE ADJUSTMENTS/MODIFICATIONS/DELAYS ...........................................11 
6.1.9 DURATION  OF THERAPY  ..................................................................................11 
6.2 STUDY  AG ENT  ACCOUNTABILITY  PROCEDURES  ...........................................11 
7 STUDY PROCEDURES  AND  SCHEDULE  .............................................................11 
7.1 STUDY  PROCEDURES/EVALUATIONS  ..................................................................[ADDRESS_851110]  OF CARE STUDY  PROCEDURES  ..............................................11 
7.1.3 Informed Consent  .............................................................................................. 11 
7.1.4 Inclusion/Exclusion Criteria ..................................................................................12 
7.1.5  Demographics and Medical History  ......................................................................12 
7.1.6  Baseline Symptoms .............................................................................................. 12 
7.1.7  Eastern Cooperative Oncology Group (ECOG) Performance Status  ....................12 
7.1.8    Concomitant Medications Review  ........................................................................12 
7.1.9  Adverse Event Review  .........................................................................................12 
7.1.10  Physical Exam  ......................................................................................................12 
7.1.11  Vital Signs  ............................................................................................................12 
7.1.12  Laboratory Procedures  .........................................................................................12 
7.1.13  Bone Marrow Biopsy  ............................................................................................ 13 
7.1.14  Correlative Studies  ...............................................................................................13 
7.1.15  CSF for ALL Involvement/IT Chemotherapy  .........................................................[ADDRESS_851111] Scan…………………………………………………………………………… …….13  
7.2 LABORATORY PROCEDURES/EVALUATIONS .....................................................13 
7.2.1 CLINICAL  LABORATORY EVALUATIONS  .......................................................13 
7.2.2  OTHER  ASSAYS OR PROCEDURES  ..............................................................14 
7.3 STUDY  SCHEDULE  ................................................................................................. 14 
7.3.1 SCREENING  ........................................................................................................14 
7.3.2 ENROLLMENT/BASELINE/STUDY VISITS  .........................................................15 
7.3.3 FOLLOW -UP ................................ ................................. .......................................19 
7.3.4  FINAL  STUDY  VISIT  .........................................................................................19 
7.3.5  EARLY TERMINATION VISIT  ..........................................................................19 
7.3.6  UNSCHEDULED VISIT  .....................................................................................19 
7.3.7  SCHEDULE OF EVENTS  TABLE ..................................................................... 20 
7.4 CONCOMITANT  MEDICATIONS,  TREATMENTS,  AND PROCEDURES  ...........21 
7.5 JUSTIFICATION  FOR  SENSITIVE PROCEDURES  .................................................21 
7.5.
1 PRECAUTIONARY MEDICATIONS, TREATMENTS,  AND PROCEDURES  .22 
7.6 PROHIBITED MEDICATIONS,  TREATMENTS,  AND PROCEDURES  ..................22 
7.7 PROPHYLACTIC  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  ............22 
7.8 RESCUE  MEDICATIONS,  TREATMENTS,  AND PROCEDURES  ........................22 
8 ASSESSMENT  OF SAFETY ...................................................................................22 
8.1 SPECIFICATION  OF SAFETY PARAMETERS  ........................................................22 
8.1.1  DEFINITION OF ADVERSE EVENTS (AE)  ....................................................22 
8.1.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  ................................[ADDRESS_851112]  ................................................................... 26 
8.4.5 REPORTING OF PREGNANCY ........................................................................26 
8.5 STUDY  HALTING  RULES  .........................................................................................27 
8.6 SAFETY  OVERSIGHT  ..............................................................................................27 
9 CLINICAL  MONITORING  .........................................................................................27 
10 STATISTICAL  CONSIDERATIONS  ..........................................................................28 
10.1 STATISTICAL  AND ANALYTICAL  PLANS ............................................................28 
10.2 STATISTICAL  HYPOTHESES .................................................................................28 
10.3 ANALYSIS DATASETS  .............................................................................................28 
10.4 DESCRIPTION OF STATISTICAL  METHODS  .......................................................28 
10.4.1  GENERAL  APPROACH .....................................................................................28 
10.4.2 ANALYSIS OF THE  PRIMARY  EFFICACY ENDPOINT(S)  ............................28 
10.4.3  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  ..........................................29 
10.4.4  SAFETY ANALYSES .........................................................................................29 
10.4.5 ADHERENCE  AND RETENTION  ANALYSES  .................................................29 
10.4.6 BASELINE DESCRIPTIVE  STATISTICS  ...........................................................29 
10.4.10  TABULATION OF INDIVIDUAL RESPONSE DATA .............................29 
10.4.11  EXPLORATORY  ANALYSES  .............................................................30 
10.5  SAMPLE SIZE ..........................................................................................................30 
10.6 MEASURES TO MINIMIZE  BIAS  .............................................................................30 
10.6.1 ENROLLMENT  ...................................................................................................30 
11 SOURCE  DOCUMENTS AND  ACCESS TO SOURCE  DATA/DOCUMENTS  ...30  
12 QU
ALITY  ASSURANCE  AND  QUALITY  CONTROL  .............................................30 
13 ETHICS/PROTECTION  OF HUMAN SUBJECTS ...................................................[ADDRESS_851113]  .........................................................................31 
13.3 INFORMED CONSENT  PROCESS .........................................................................31 
13.3.1 CONSENT/ASSENT  AND OTHER  INFORMATIONAL  DOCUMENTS  PROVIDED 
TO PARTICIPANTS  .............................................................................................[ADDRESS_851114]  POLICY  ........................................................................32 
16 LITERATURE  REFERENCES  .................................................................................32 
APPENDIX A Response Criteria  .............................................................................................32 
APPENDIX B ECOG Performance Status…………………………………………………..……..[ADDRESS_851115]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851116] 
IB Investigator’s  Brochure  
ICH International  Conference  on Harmonisation  
ICH E6 International  Conference  on Harmonisation  Guidance  for Industry,  Good  Clinical  Practice:  
Consolidated  Guidance  
IND Investigational  New  Drug  Application  
IRB Investigational  Review  Board  
IT Intrathecal  
LDH Lactate Dehydrogenase  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MOP  Manual  of Procedures  
MRD  Minimal Residual Disease  
OHRP  Office  for Human  Research  Protections  
PI [INVESTIGATOR_636625]: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 vii [ZIP_CODE]  STATEMENT OF COMPLIANCE   
 
The trial will be conducted  in accordance  with the ICH E6, the Code  of Federal  Regulations  on the 
Protection  of Human Subjects  (45 CFR Part 46). The Principal  Investigator  [INVESTIGATOR_636626], or changes  to the protocol  will take  place without  prior  agreement from  the sponsor  and 
documented approval  from  the Institutional  Review  Board , except  where  necessary  to eliminate  an 
immediate  hazard(s)  to the trial participants.  All personnel  involved  in the conduct  of this study  have  
completed  Human  Subjects  Protection  Training.  
 
I agree  to ensure  that all  staff  members  involved  in the conduct  of this study  are informed  of their  
obligation to meet  the above  commitments.  
 
 
Principal  Investigator:    [INVESTIGATOR_636624], MD    
 Print/Type  Name  
 
 
[INVESTIGATOR_14586]:      Date:   
LIST  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 viii [ZIP_CODE]  STUDY  SUMMARY   
 
Title:  A Single -Arm, Open -Label Phase 2 Pi[INVESTIGATOR_636623] ( CPX-351) in Adults 
with Relapsed or Refractory Acute Lymphoblastic Leukemia. 
 Objectives:  Primary  Objective:   
1) To estimate the complete response rate following treatment with CPX-351 
 
Important  Secondary  Objectives:   
1) To evaluate the safety and tolerability of CPX -351 
2) To estimate minimal residual disease burden following treatment with CPX-351 
3) To estimate the progression free survival (PFS) following treatment CPX -
351 
4) To estimate the overall survival (OS) following treatment with CPX -351 
 
Endpoint  Primary  Endpoint:  
 1) Complete remission rate  
  Important  Secondary  Endpoints:   
1) To evaluate the safety and tolerability of CPX -351 
2) Minimal Residual Disease Burden  
3) PFS 
4) OS 
 
Population: Patients >18 years old with relapsed acute  lymphoblastic leukemia (ALL) who 
are registered at the Moffitt Cancer Center.  
 Phase:  
2, pi[INVESTIGATOR_636627]:  1 
 
Description of  Study   
Agent  : 
1) Induction: Vyxeos ( CPX-351) , 100 units/m
2 days 1, 3, & 5  
2) Consolidation: Vyxeos (CPX -351) 65 units/m2 days 1 & 3 (up to 3 
cycles)  
 
Study  Duration: 24 months  
 
Participant  Duration: [ADDRESS_851117]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 ix [ZIP_CODE]   
 
 
 
Induction  CPX-351 100 u/m2   90 minute infusion days 1,3,5  
Consolidation  
Per section [IP_ADDRESS]  CPX-351  65 u/m2   90 minute infusion days 1,3  
(administered 35 -75 days after start of induction) for up to [ADDRESS_851118]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851119]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 1 [ZIP_CODE]  
 
Principal Investigator:   
[INVESTIGATOR_636624], MD     
Moffitt Cancer Center     
[ADDRESS_851120]. FOB -3 
Tampa, FL [ZIP_CODE]     
[PHONE_13240]     
[EMAIL_12130]    
 
Sub-Investigator:  
Jianguo Tao, MD, PhD  
Department of Hematopathology  
Moffitt Cancer Center  
[ADDRESS_851121].  
Tampa, FL [ZIP_CODE]  
[PHONE_13241]  
[EMAIL_12131]  
 
Sub-Investigator:  
Jason Brayer, MD, PhD  
Department of Malignant Hematology  
Moffitt Cancer Center  
[ADDRESS_851122].  Tampa, FL [ZIP_CODE]  
[PHONE_13242]  
[EMAIL_12132]
 
 
Statistician:  
Jongphil Kim, PhD  
Department of Biostatistics and Bioinformatics  
Moffitt Cancer Center  
[ADDRESS_851123].  Tampa, FL [ZIP_CODE]  
[PHONE_703]  
[EMAIL_12133]
 
 
Clinical Research Nurse:  
Elyce T urba, MSN, RN, OCN  
Moffitt Cancer Center     
[ADDRESS_851124]. FOB 3    
Tampa, FL [ZIP_CODE]     
[PHONE_13243] 
[EMAIL_12134]  
 
 
 
 
Outcomes are poor among adults with relapsed and refractory ALL, with most chemotherapy regimens 
demonstrating a  CR rate of ~40%, coupled with a median EFS of ~6mo. (ref 1 -10). To this end, several 
1 KEY ROLES  
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
2.[ADDRESS_851125]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851126] emerged,  including blinatumomab (CR/CRi rate 43%, med OS 7.7mo), inotuzumab 
ozagomycin (CR/CRi rate 80.7%, med OS  7.7mo), and liposomal vincristine (CR/CRi rate 20%, 6mo OS 
35%). (ref 11 -13). While these therapi[INVESTIGATOR_636628], relapse and 
shortened life expectancy remain the expectation for most patients.  
Chemotherapy resistance has been related in part to the overexpression of cell proteins implicated in 
drug transmembrane transport, such as PGP and LRP. (ref 14 -18). Attempts to int ensify therapy by 
[CONTACT_636645]. (ref 8 -9,19). More  recently, trials using liposomal daunorubicin in conjunction with 
high dose cytarabine demonstrat ed improved clinical efficacy (CR 80%, 12mo OS 39%). Notably, in cells 
from those with increased expression of multi -drug resistant proteins  (72% of patients), the in vitro 
retention of liposomal daunorubicin and subsequent apoptosis were both significantly higher,  when 
compared with free daunorubicin. (ref 18) Recent work further suggests molar ratio of cytarabine:daunorubicin, in  addition to drug uptake, may be important in yielding therapeutic 
response. (ref 20 -21) 
 CPX-351 (or Vyxeos) is a liposomal formulation of cytarabine and daunrobicin at a fixed molar ratio.  A 
randomized study of CPX -351 (vs non -liposomal cytarabine and daunorubicin) in high risk acute 
myeloid leukemias demonstrated a significant benefit in complete remission rates (47.7% vs 33.3% ) 
and median overall survival (9.56 vs. 5.95 months), culminating in FDA approval August 2017.   
 Preclinical and early clinical data using primary ALL cell samples suggest s that this benefit may extend 
to those with lymphoblastic leukemias.  Specifically,  “high sensitivity” to CPX -351 was observed  in 20% 
of samples. (ref 22). This was  further corroborated with xenograft modeling using samples derived 
from pediatric patients with relapsed ALL , wherein response was estimated via ORM modeling to be 
100%, with  response in 4 of 5 mouse groups suggestive of  CR. Notably, activity was also observed in a 
Philadelphia chromosome positive patient derived xenograft. (ref 23) Finally,  CPX-351 was also tested 
clinically during phase 1 testing in 3 patients with ALL, with  one showing subsequent CR. (ref  24) 
 Based on these data, the author believes there is rationale for further study of this approach in 
relapsed and refractory ALL.  
 
 
Remission rates vary considerably depending on population studies (children vs adults), relapsed vs refractory  status, and timing of salvage (first relapse vs beyond first relapse) making it difficult t o 
extrapolate baseline rate. If focusing specifically on 2 trials that used an induction composed of cytarabine (3gm/m2 x5d) and idarubicin (40mg/m2 on d3), complete remission rates are approximately 40% (38 -44%, total n=54). (ref 4 -5). Alternatively, a more recent phase [ADDRESS_851127] of care arm (Cytarabine+Mitoxantrone,high dose Cytarabine, and Fludarabine, Cytarabine, and GCSF, total n=109) of 29%. (ref 13). Given these data, it is determined that  a baseline 
CR rate of 35% is likely to estimate activity with a stan dard salvage regimen.  
 
Data using liposomal anthracyclines among those with relapsed ALL, including FLAD (Fludarabine, 
Cytarabine, Liposomal Daunorubicin) and Cytarabine+Liposomal Daunorubicin, have shown an 
improvement in CR rates, at 65% and 80%, respectively. (ref 18,28) Together these data suggest a CR rate of 65% should be attainable using CPX -351.  
 However, at this stage, a phase [ADDRESS_851128]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851129] historical regimens noted above.  
Adverse events of special interes t include bone marrow aplasia (h ypocellular marrow without 
adequate count recovery >42 days from start of therapy), and symptomatic heart failure ( accompanied 
by a decrease in  the ejection fraction >10% from baseline greater than 42 days from start of therapy).  
 
 
 
 
The table below summarizes adverse reactions obtained directly from the Investigator Brochure  
Version  13.0. The table includes pooled data from five clinical trials of 375 patients with AML. The 
frequency   is referenced using the following MedDRA scale:  
∙ Very common: ≥1/10 (≥10%);  
∙ Common (frequent): ≥1/100 and <1/10 (≥1% and <10%);  
∙ Uncommon (infrequent): ≥1/1,000 and <1/100 (≥0.1% and <1%);  
∙ Rare: ≥1/10,000 and <1/1,000 (≥0.01% and <0.1%);  
∙ Very rare: <1/10,000 (<0.01%), including isolated reports.  
 
System Organ Class    
 All AEs/Frequency  Grade 3 -5 AEs/Frequency  
Blood and lymphatic system disorders  Very Common  
Febrile neutropenia  
Common  
Neutropenia  
Thrombocytopenia  
     Anemia  Very Common  
Febrile neutropenia  
Common  
Neutropenia  
Thrombocytopenia  
     Anemia  
Cardiac disorders  Very Common  
    Cardiotoxicity  
    Arrhythmia  
    Chest pain  Very Common  
Cardiotoxicity  
 Common  
Arrhythmia  
    Chest pain  
Eye disorders  Very Common  
    Visual impairment  Uncommon  
     Visual impairment  
Gastrointestinal disorders  Very Common  
    Mucositis  
    Abdominal pain  
    Constipation  
    Decreased appetite  
    Diarrhea/colitis  
    Nausea  
    Vomiting  
 Common  
    Dyspepsia  Common  
Mucositis  
Abdominal pain  
Constipation  
Decreased appetite  
Diarrhea/colitis  
Nausea  
Uncommon  
Vomiting  
     Dyspepsia  
General disorders and administration site 
conditions  Very Common  
     Edema       
Pyrexia  
Fatigue 
    Chills  Very Common  
Fatigue 
Common  
Edema  
Pyrexia  
Uncommon  
    Chills  
Immune system disorders  Very Common  
     Hypersensitivity  Common  
     Hypersensitivity  
Infections and infestations  Very  Common  
     Infection  Very Common  
     Infection  
Metabolism and nutrition disorders  Common  
     Tumor lysis syndrome  Common  
     Tumor lysis syndrome  
2.[ADDRESS_851130]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 4 [ZIP_CODE]  Musculoskeletal and tissue disorders  Very Common  
     Musculoskeletal pain  Common  
     Musculoskeletal pain  
Nervous system disorders  Very Common  
    Headache  
    Dizziness  Common  
     Headache  
 Uncommon  
      Dizziness  
Psychiatric disorders  Very Common  
Delirium  
Sleep disorders  
     Anxiety  Common  
Delirium  
Uncommon  
     Sleep disorders  
Renal and urinary disorders  Very Common  
    Renal insufficiency  Common  
    Renal insufficiency  
Respi[INVESTIGATOR_696], thoracic and mediastinal 
disorders  
 Very Common  
     Dyspnea  
     Pleural effusion  
     Cough  Very Common  
     Dyspnea  
Uncommon  
     Pleural effusion  
Skin and subcutaneous disorders  Very Common  
     Pruritis  
     Hyperhidrosis  
Common  
     Alopecia  
     Night sweats  
Uncommon  
    Palmar -plantar  
    erythrodysesthesia  syndrome  Uncommon  
    Hyperhidrosis  
Vascular disorders  Very Common  
    Hemorrhage  
    Hypertension  
    Hypotension  Very Common  
     Hemorrhage  
Common  
    Hypertension  
    Hypotension  
 
 
 
 
 
Initial work with primary ALL cell samples suggested “high sensitivity” to CPX -351 in 20% of samples. (ref 
22). This was further corroborated with xenograft modeling using samples derived from pediatric patients 
with relapsed ALL. Specifically, response was estimated via ORM modeling to be 100%, with response 4 of 5 mouse grou ps suggestive of CR. Notably, activity was also observed in a Philadelphia chromosome 
positive patient derived xenograft. (ref 23) Finally, CPX -351 was also tested clinically during phase 1 testing  
in 3 patients with ALL, with one showing subsequent CR. (r ef 24) Based on these data, there is reason to 
believe there could be benefit to subjects with relapsed and refractory ALL.  
 To date we have treated [ADDRESS_851131] seen CR in two patient s and PR in 3 other 
evaluable patients  following induction  (ORR 83%).  Relevant grade 3 -5 SAE’s to date include: bleeding, 
veno -occlusive disease of the liver, and fungal pneumonia.  
 
 
Primary  Objective:   
To estimate the complete response rate following treatment with CPX -351.  Complete remission will 
be evaluated by [CONTACT_636646] [ADDRESS_851132] or PET/CT 
will be used for response. Cheson  criteria (2003) will be used to evaluate remission status, specifically 
complete remission (CR), complete remission with incomplete hematologic recovery (CRi/CRh), partial response (PR), and aplasia.    Important  Secondary  Objectives:  
2.3.[ADDRESS_851133]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 5 [ZIP_CODE]  Additional clinical endpoints will include  
1) To evaluate safety and tolerability of CPX -351 using CTCAE 5.0 . 
2) Minimal residual disease assessment (MRD) by 10 color flow cytometry and next generation 
sequencing (NGS) by [CONTACT_636647] (for Philadelphia negative leukemia) or PCR for BCR- ABL (for 
Philadelphia positive leukemia).   
3) Progression Free Survival as defined by [CONTACT_636648], namely progression, failure to respond, or 
death, as assessed from time of first treatment.  
4) Overall Survival as defined by [CONTACT_636649], namely death due to any cause as assessed from 
time of first treatment.  
 
 
 
 
 
This is an o pen label, single arm, single center, phase 2 pi[INVESTIGATOR_636629] &  
consolidation in relapsed and refractory ALL.  
 
 
 
 
• We will measure remission rate at day 28 to address the primary endpoint of complete remission (with or without complete hematologic recovery) , as defined by [CONTACT_636648] (ref 27) .  For those with 
extramedullary disease, Lugano criteria will be used to assess response  (ref 32) . This is a standard 
assessment of drug efficacy for phase 2 clinical trial design in acute leukemias, as response cor relates 
closely with progression free - and overall survival (PFS and OS) . 
 
 
Secondary Endpoints will include  
1) Evaluation of safety of CPX -351 using CTCAE 5.0 .   
2) Minimal residual disease assessment (MRD) by 10 color flow cytometry and next generation sequencing (NGS) by [CONTACT_636647] (for Philadelphia negative leukemia) or PCR for BCR -ABL (for 
Philadelphia positive leukemia) at day 28.   Using a threshold of 0.01% leukemic cells, MRD provides 
a better estimate leukemic cell sensitivity to therapy , and correlates with both PFS and OS.   
3) Progression Free Survival as defined by [CONTACT_636650] (ref 27  and 32 ), namely 
progression, failure to respond, or death, as assessed from time of first treatment.  The [ADDRESS_851134] chemotherapeutic approaches in relapsed ALL is 
estimated at 10%.  PFS is a standard estimate that accounts for response rate, response duration, and mortality to estimate therapeutic benefit in clinical trials.   
4) Overall Survival as defined by [CONTACT_636651] (ref 27  and 32 ), namely death due to any 
cause as assessed from time of first treatment.  The [ADDRESS_851135] c hemotherapeutic approaches in relapsed ALL estimated at 20%.  Overall survival is a 
standard criteria for assessing therapeutic benefit in clinical trials.  
 
 
 Exploratory Endpoints will include:  
1) An exploration of the activity of CPX -351 ex vivo using live image capture in a reconstituted tumor 
micro -environment (EVOS system) as a potential biomarker for response.   
[ADDRESS_851136]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 6 [ZIP_CODE]  2) An assessment of apoptotic threshold as a measure of tumor cell fitness (dynamic BH3 profiling). 
These data may additionally support combinatorial approaches using clinical inhibitors of apoptosis.  
3) An assessment of the T- cell repertoire using multi-parameter flow, and tumor/stromal PDL1 
expression.  These data will similarly be used to  support potential future combinatorial strategies.  
 
 
 
 
 
      Patients must meet all of the following criteria to be eligible for study entry:  
 
1. Be willing and able to provide written informed consent/assent for the trial.  
 
2. Be ≥ 18 years of age on day of signing informed consent.  
3. Able to adhere to the study visit schedule and other protocol requirements.  
4. Pathologically confirmed B- or T-cell acute lymphoblastic or mixed phenotype acute leukemia, with 
>5% peripheral blood or bone marrow lymphoblasts and/or extramedullary disease >1x1cm.  
 
5. Relapsed or refractory acute lymphoblastic leukemia after at least [ADDRESS_851137] two prior tyrosine kinase inhibitors. 
 
6. Eastern Cooperative Oncology Group (ECOG) performance status 0 -1. 
 
7. Cardiac ejection fraction ≥ 50% by [CONTACT_41230].  
 
8. Must be at least 2 weeks out from any pr ior systemic chemotherapy, blinatumumab, radiation, 
and/or other investigational agents, and have recovered to grade [ADDRESS_851138] dose.  
 
9. Serum bilirubin and crea tinine < 1.5x upper limit of normal (ULN).  AST and ALT must be < 3x  ULN, 
unless there is  suspected  liver involvement. 
 
10. Females of childbearing potential (FCBP) must have a negative serum pregnancy test at screening. A FCBP is considered when a sexually ma ture female: 1) has not undergone a hysterectomy or bilateral 
oophorectomy; or 2) has not been naturally postmenopausal for at least [ADDRESS_851139]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 7 [ZIP_CODE]  Any of the following is a criterion for exclusion from the study: 
1. Clinical evidence of active central nervous system (CNS) leukemia.  
 
2. Any major surgery or radiation therapy within four weeks.  
 
3. Any active infection requiring systemic therapy, including HIV, Hepatitis B, and/or Hepatitis C.  
 
 
4. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opi[INVESTIGATOR_44984] (including but not  limited to severe graft -versus -host disease, unstable angina, 
pulmonary hypertension, active/prior veno -occlusive disease of the liver, or severe CHF (NYHA III -
IV).  
5. Patients with active (uncontrolled, metastatic) second malignancies are excluded.  
6. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected 
duration of the trial, starting with the screening visit through [ADDRESS_851140] dose of trial 
treatment.  
7. Hypersensitivity to cytarabine, daunorubicin, or liposomal products.  
 
8. History of Wilson’s disease or other copper- metabolism disorder.  
9. Patients with prior cumulative anthracycline exposure of greater than 368 mg/m
2 daunorubicin  
(or equivalent). 
 
 
 
Recruitment of the 10 participants for this trial will occur from new or established patients treated at 
the Hematology Clinic at Moffitt Cancer Center. Screen failure is anticipated to be less than 10%. The 
target accrual is expected to be reached in 24 months. All faculty members in the Lymphoma Section 
will be sub -investigators on the trial. They will be trained on the trial design, study agents, and eligibility 
criteria. This will equip each investigator to discuss the trial with potential participants as appropriate. The trial will be listed on the Moffitt Cancer Center website (www.moffitt.org) for the availability of local 
physicians to refer patients who could be eligible for the trial.   
All investigators will be made aware of the emphasis to enroll women and minorities. The design of the 
trial and eligibility criteria are not restrictive relative to women and minorities.  According to the  National 
Cancer Institute Surveillance, Epi[INVESTIGATOR_623], and End Results Program, there are approximately 60 00 
new cases of ALL per yea r, of which nearly half will occur among those over age 20 years. (ref. 29) In a 
currently enrolling Moffitt trial ( MCC18329) for patients  with ALL, 50% of participants were young adults 
(age 18 -39), 25% were female,  and 100% were Hispanic /Portuguese . The sex, ethnicity, and race of each 
participant on this trial will be captured in the Oncore electronic data base for reporting purposes.   The multi -modal aspect of this disease will require knowledge of the barriers to recruitment and 
retention present to young adults, older adults, and those who may be Hispanic.  The young adult 
population can be challenging to interest in trial participation. The article by [CONTACT_636652] ( ref. 30) provides 
understanding of communication strategies, the need of young adults to feel autonomous, and the importance young adults place on being treated in a specialist care setting to facilitate trial participation. 
5.[ADDRESS_851141]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851142] may be withdrawn by [CONTACT_20616] r if enrollment into the trial is inappropriate, the trial plan is 
violated, or for administrative and/or other safety reasons.   
 
A subject must be discontinued from the trial for any of the following reasons:  
• The subject or legal representative (such as a parent or legal guardian) withdraws consent  
• Unacceptable adverse events  
• Intercurrent illness that prevents further administration of treatment  
• Investigator’s decision to withdraw the subject  
• The subject has a confirmed positive serum pregnancy test  
• Nonco mpliance with trial treatment or procedure requirements  
• The subject is lost to follow -up 
• Administrative reasons  
 
The End of Treatment and Follow- up visit procedures are listed in the Schedule of Events and Section 
7.3 (Visit Requirements).  After the end o f treatment, each subject will be followed for [ADDRESS_851143] to 
follow -up (unsuccessful attempts to contact [INVESTIGATOR_8178] 3 months).  After documented disease progression , 
each subject will be followed [ADDRESS_851144]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851145] 1 day of therapy will be evaluable for safety.  Replacement of participants 
is permitted for those who screen fail or drop out prior to completing initial response assessment at day 
28 of treatment, in order to meet the accrual goal of this study.  
 
 
 
This study  may  be temporarily  suspended or prematurely  terminated if there is sufficient reasonable  
cause.  Written  notification,  documenting the  reason for  study  suspension or termination,  will be 
provided by [CONTACT_636653],  funding agency,  the IND/IDE  sponsor  
and regulatory  authorities.   If the study  is prematurely  terminated  or suspended,  the PI [INVESTIGATOR_636630](s)  for the termination  or suspension.  
 
Circumstances  that may  warrant  termination  or suspension include,  but are not limited  to: 
1. Quality or quantity of data recording is inaccurate or incomplete  
2. Poor adherence to protocol and regulatory requirements  
3. Incidence or severity of adverse drug reaction in this or other studies indicates a potential health 
hazard to subjects  
4. Plans to modify or disc ontinue the development of the study drug 
5. Determination of futility  
In the event Jazz Pharmaceuticals, Inc.  decides to no longer supply study drug, ample notification will 
be provided so that appropriate adjustments to subject treatment can be made.  
 
 
 
 
 
 
Study  agent  will be supplied by  [CONTACT_636654]/IDE  sponsor to the Moffitt Research Pharmacy.  
 
 
• CPX-351 ( Vyxeos) is stored as a dry powder at 2ºC to 8ºC  
• CPX-351 (Vyxeos) is provide d by [CONTACT_156239].   
• CPX-351 is FDA approved and commercially marketed for patients with Acute Myeloid 
Leukemia  
• For this trial we will be using investigational supply for th is trial in Acute Lymphoblastic 
Leukemia.   
 
 
 Vials of CPX -351 should be refrigerated prior to use (at 2 -8oC) and should be utilized prior to expi[INVESTIGATOR_636631]. If reconstituted product is not diluted into an infusion bag 
immediately, store in refrigerator at 2ºC to 8ºC for up to 4 hours.  
 
5.5 PREMATURE  TERMINATION  OR SUSPENSION  OF STUDY  
6 STUDY  AGENT  
6.1 STUDY  AGENT(S)  AND  CONTROL  DESCRIPTION  
6.1.[ADDRESS_851146]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 10 [ZIP_CODE]   
The appropriate number of vials of CPX -351 (cytarabine:daunorubicin) Liposome Injection should be 
removed from the refrigerator , and allowed to equilibrate to room temperature for [ADDRESS_851147] for 15 minutes.  After reconstitution (but before final dilution) , the 
concentration is 5 u/mL. .  The reconstituted product should be an opaque, purple, homogeneous 
dispersion, essentially free from visible particulates.   Gently invert each vial [ADDRESS_851148] from the vial(s) with a sterile 
syringe and transfer it to an infusion bag containing 500 mL of 0.9% Sodium Chloride Injection, USP or 
5% Dextrose Injection, USP. There may be residual  product remaining in the vial. Discard unused 
portion.  Gently invert the bag to mix the solution. The dilution of the reconstituted product results in a 
deep purple, translucent, homogeneous dispersion, free from visible particulates.  If the diluted inf usion 
solution is not used immediately, store in refrigerator at 2ºC to 8ºC for up to [ADDRESS_851149] be strictly observed 
throughout the handling of CPX -351 (cytarabine:daunorubicin) Liposome Injection since no 
bacteriostatic agent or preservative is present. The infusion of CPX -351 (cytarabine:daunorubicin) 
Liposome Injection must be started within 4 hours of dilution. Vials are for single use. Unused material 
should be recorded as such and discarded according to institutional  policies. Procedures for proper 
handling and disposal of anticancer drugs should be implemented.
 
 
 
 
The infusion of CPX -351 (cytarabine:daunorubicin) Liposome Injection will be performed through  a 
central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period. Non -DEHP containing administration sets should be used. Do not use an in -line filter. CPX -
351 should never be given by [CONTACT_125620] o r subcutaneous route. Administer CPX -351 over 
approximately 90 minutes via an infusion pump. Flush the line to ensure administration of the full dose.  
 The dosage (total units and u/m
2), start/stop time of the infusion, total volume infused, must be 
docume nted in the patient’s chart.  
 
 
Patients will receive induction with CPX -351 at a dose of 100 u/m2 administered intravenously over 90 
minutes on days 1, 3 and 5 of a 28 day cycle.   
 
This may be followed by [CONTACT_636655] -351 at a dose of 65 u/m2 administered intravenously 
over [ADDRESS_851150] STORAGE AND STABILITY  
6.1.5  DOSING  AND  ADMINISTRATION & ROUTE OF ADMINISTRATION  
6.1.[ADDRESS_851151]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 11 [ZIP_CODE]   
It is the intention of the study to treat every patient at full dose. Doses may be delayed due to toxicities 
(for example hypersensitivity reactions). Any doses missed or delayed due to toxicity may be administered as soon as the patient has recovered from the toxicity.  
 
 
All patients completing induct ion will be evaluable for efficacy.  Consolidation may be started at the 
time of hematologic recovery ( 28-75 days after start of induction) for those achieving a complete 
remission or complete remission with incomplete hematologic recovery.  Consolidation cycles may be 
repeated at the time of hematologic recovery for a maximum total of [ADDRESS_851152] received from the Sponsor. Records of storage conditions (temperature logs) must be kept for the entire period that CPX -351 is maintained 
at the institution.  
 
 
 
 
 
 
The Schedule of Events - Section 7.3.7 summarizes the trial procedures to be performed at each visit.  
Individual trial procedures are described in detail below.  It may be necessary to perform these 
procedures at unscheduled time points if deemed clinically necessary by [CONTACT_093].  
 
Furthermore, additional evaluations/testing may be deemed necessary by [CONTACT_978] [INVESTIGATOR_1238]/or Jazz 
Pharmaceuticals for reasons related to subject safety. In some cases, such evaluation/testing may be 
potentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations may require that additional consent be obtained from the su bject.  In these cases, such evaluations/testing will be 
performed in accordance with those regulations.  
 
 
The majority of procedures and laboratory tests on this trial will performed per standard of care for ALL.  
Standard of care screening testing will include: b one marrow biopsy, echo cardiogram /MUGA, EKG, 
serum pregnancy test, physical examination, CBC/differential, serum chemistry , vital signs , CSF/IT 
chemotherapy. During hospi[INVESTIGATOR_059], laboratory testing, sup portive care measure, and procedures will 
be following standard of care as for any other ALL treatment .  
 
 
 
Prior to any study procedure  that is not considered standard of care, informed consent must be 
obtained and documented by [CONTACT_423]’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally acceptable 
representative’s dated signature [INVESTIGATOR_2394] a consent form. The dated signature [CONTACT_636671].  
6.1.8  DOSE  ADJUSTMENTS/MODIFICATIONS/DELAYS  
6.1.9  DURATION  OF THERAPY  
6.2 STUDY  AGENT  ACCOUNTABILITY  PROCEDURES  
7 STUDY  PROCEDURES  AND  SCHEDULE  
7.1 STUDY  PROCEDURES/EVALUATIONS  
7.1.[ADDRESS_851153]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851154] time before the start of study drug administration.  
 
 
The investigator or qualified designee will assess ECOG status (see Appendix B) as specified in the 
Schedule of Events.   
 
       
 
The investigator or qualified designee will record medication, if any, taken by [CONTACT_636656].  All medications related to reportable SAEs should be recorded as defined in the SAE section of the protocol.  
 
 
The investigator or qualified designee will assess each subjec t to evaluate for potential new or 
worsening AEs as specified in the Schedule of Events and more frequently if clinically indicated.  Adverse events will be collected from the time of consent until [ADDRESS_851155] dose or until 
subsequent anti -leukemic therapy for those failing to show adequate response.  
 
 
The investigator or qualified designee will perform a complete physical exam during the screening period.  Clinically significant abnormal findings should be recorded as medical history.   
 
 
The investigator or qualified designee will take vital signs at screening and prior to the administration 
of each dose of trial treatment. Vital signs should include temperature, pulse, respi[INVESTIGATOR_697], weight and blood pressure.  Height will be measured at screening only.  
 
7.1.4  Inclusion/Exclusion Criteria  
7.1.5  Demographics and Medical History  
7.1.6  Baseline Symptoms  
7.1.7  Eastern Cooperative Oncology Group (ECOG) Performance Status  
7.1. [ADDRESS_851156]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 13 [ZIP_CODE]  At screening laboratory procedures will include a CBC with differential, CMP  (albumin, BUN, creatinine, 
alkaline phosphatase, ALT, AST, CO2, calcium, chloride, glucose, potassium, sodium, total bilirubin, 
total protein) , LDH, uric acid, magnesium, phosphorus, coagulation studies, and urinalysis with 
microscopy. Laboratory testing on day one and during the hospi[INVESTIGATOR_60521], EOT, and follow -up 
will be at physician discretion per standard of care.  
 
A bone marrow biopsy will be performed at screening and at day 28. If determined the subject has 
extramedullary disease (as permitted in inclusion criterion #4), biopsy of the involved area will be the 
method by [CONTACT_636657], provided this can be safely obtained. If 
extramedullary disease is confirmed and the bone marrow biopsy is shown to be negative prior to trial participation, no bone marrow biopsy will be required at day 28. If subject discontinues treatment ear ly 
or progression of disease is suspected, a bone marrow biopsy will be done at the discretion of the 
investigator. During follow -up, bone marrow biopsies will be performed per investigator discretion.  
 
 
Three different tests will be performed during the course of the trial. At screening, samples  will be 
collected from bone marrow aspi[INVESTIGATOR_67955]. If determined the subject has 
extramedullary disease (as permitted in inclusion criterion #4), b iopsy of the involved area will be the 
method by [CONTACT_636658] . Biopsy will involve at least [ADDRESS_851157] may still participate in the trial without collection of the correlative samples.  At the day 
28 time point, the samples will be obtained from peripheral blood. Correlatives will be performed at investigator’s discretion if early study termination. For sampling requirements, see Section 7.2.  
 
 
If a potential study subject demonstrates clinical signs or symptoms of CNS involvement, a CSF sample will be obtained through a spi[INVESTIGATOR_122499]. If CNS involvement is confirmed, the subject will not be eligible for study participation. Provided there are no contra-indications, p rophylactic intrathecal methotrexate will be 
administered per standard of care, [ADDRESS_851158] extramedullary disease as permitted by [CONTACT_461630] #4, the method for baseline disease assessment will be CT or PET/CT scan per standard of care. This method will 
also be used for determining response as sessment on Day 28.  
 
 
 
 
• Hematology : hemoglobin,  hematocrit,  white  blood cells  (WBC)  with  differential  count,  platelet  
count.  
• Metabolic Panel : albumin, BUN, alkaline phosphatase, CO2, calcium, chloride, 
glucose, potassium, sodium, total protein, LDH, uric acid, magnesium, phosphorus, creatinine,  total  bilirubin,  alanine  aminotransferase (ALT),  aspartate  
aminotransferase  (AST).  
7.1.13  Bone Marr ow Biopsy  
7.1.14  Correlative Studies  
7.1.15  CSF for ALL Involvement/IT Chemotherapy  
7.1.16  Imaging  
7.2 LABORATORY  PROCEDURES/EVALUATIONS  
7.2.[ADDRESS_851159]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 14 [ZIP_CODE]  • Urinalysis : complete  urinalysis with microscopic evaluation  
• Pregnancy  test: to be done  within  [ADDRESS_851160].  
• Laboratory testing on day one and during the hospi[INVESTIGATOR_60521], EOT, and follow -up will 
be at physician discretion per standard of care.  
 
 
 
 
1. To explore the activity of CPX -351 ex vivo using live image capture in a reconstituted tumor micro -
environment (EVOS system) as a potential biomarker for response:  Primary patient ALL cells will 
be seeded into a 384 -well plate onto reconstructed TME, which includes extracellular matrix 
(collagen 1) and human bone marrow derived stromal cells (BMSC).  CPX -351 dosed at 5 different 
concen trations will be added to the media, and plate is then continuously imaged for 96 hours.  A 
digital image analysis algorithm detects tumor cells based on cell size and membrane motion. Changes in viability are quantified by [CONTACT_636659] (AUC).  HBL -2 cells are used as a control.  
 
2. To identify potential drug candidates for future combinatorial approaches, including assessment of the T -cell repertoire , PDL1 expression  by [CONTACT_636660], and BH3 
profiling.   
T-cell assessment:   Leukocytes will be isolated from BMBx aspi[INVESTIGATOR_636632]- Hypaque 
gradient separation from RBCs (and other stromal elements, in the case of BMBx aspi[INVESTIGATOR_26594]). Cells will be enumerated after [ADDRESS_851161] been designed to assess lymphocytes subsets, effector/memory maturation, and exhaustion.  
 
3. PDL1 expression : Will be determined on blasts/stroma using Dako antibody  on formalin fixed 
paraffin embedded bone marrow core biopsy slide s per routine.  
 
4. BH3 Profiling:  Briefly following membrane permeablization with digitonin, BH3 mimetic peptides targeting BIM, BAD, HRK, and MS -1 will be used to interrogate the contribution of BCL2, BCLXL, 
and MCL1 to mitochondrial outer membrane permeablization (MOMP).  The collapse of the transmembrane mitochondrial potential is used as a surrogate for MOMP, and estimated by [CONTACT_636661].  
 
5. Sampling of extramedullary disease will involve CT guided or excisional biopsy collection of 6 core 
biopsy samples (if possible ), to be divided evenly between the two investigators’ laboratories 
assigned to perform  the above tests. This will be done in accordance with the Moffitt Total Cancer 
Care (TCC)  protocol . 
 
 
 
 
 
Screening  Visit  (Day  -28 to -1)  
 
• Obtain and review  medical  history  to determine  eligibility  based  on inclusion/exclusion criteria.  
7.2.[ADDRESS_851162]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 15 [ZIP_CODE]  • Written informed consent to be obtained prior to any screening procedures  
• Review  medications  history (including over -the-counter drugs, vitamins, herbs, alcohol)  to 
determine  eligibility  based on inclusion/exclusion criteria.  
• Perform physical  examination  needed to  determine  eligibility  based  on inclusion/exclusion 
criteria 
• Vital signs  measurements  
• Evaluation of ECOG performance  status  
• Twelve- lead  ECG and Echocardiogram or MUGA.  
• Serum beta -human chorionic gonadotropin (β -hCG) pregnancy test for women of childbearing 
potential  
• Clinical laboratory testing including urinalysis, serum chemistry, hematology, and coagulation 
parameters. Clinical assessments (laboratory tests, ECHO/MUGA, EKG) performed as part of the 
subject’s routine clinical evaluation and not specifically for this study need not be repeated after signed informed consent has been obtained provided the assessments fulfill the study requirements and are performed within 28 days of starting study treatment.  
• Bone  marrow biopsy and peripheral blood sample will need to be  repeated in order to collect 
correlative samples.  
• CT or PET/CT scan of affected areas for subjects determined to have extramedullary disease or 
for staging purposes prior to treatment.  
• Spi[INVESTIGATOR_636633] c for CNS involv ement  
 
 
 
 
 
[IP_ADDRESS]  Induction Baseline Visit  (Day 1) 
 
• In-patient admission 
• Verify  subject still meets inclusion/exclusion criteria.  
• Review results of serum pregnancy test, if applicable.  
 
• Assess and record baseline symptoms prior to study drug administration.  
• CBC with differential  
• Chemistry profile (ALT, AST, alkaline phosphatase, total bilirubin, calcium, bicarbonate, 
sodium, potassium, chloride, creatinine, BUN, total protein and albumin)  
• LDH, uric acid, m agnesium, phosphorus  
• Initiation of induction therapy - study dru g administration ( CPX-351 intravenously)  
[IP_ADDRESS]  Induction Day 2  
7.3.2  ENROLLMENT/BASELINE/STUDY VISITS  
LIST  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 16 [ZIP_CODE]  • CBC with differential  
• Chemistry profile (ALT, AST, alkaline phosphatase, total bilirubin, calcium, bicarbonate, 
sodium, potassium, chloride, creatinine, BUN, total protein and albumin)  
• LDH, uric acid, magnesium, phosphorus  
[IP_ADDRESS]  Induction Day 3  
• CBC with differential  
• Chemistry profile (ALT, AST, alkaline phosphatase, total bilirubin, calcium, bicarbonate, 
sodium, potassium, chloride, creatinine, BUN, total protein and albumin)  
• LDH, uric acid, magnesium, phosphorus  
• Study drug administration (initiation of CPX -351 intravenously)  
[IP_ADDRESS]  Induction Day 4  
• CBC with differential  
• Chemistry profile (ALT, AST, alkaline phosphatase, total bilirubin, calcium, bicarbonate, 
sodium, potassium, chloride, creatinine, BUN, total protein and albumin)  
• LDH, uric acid, magnesium, phosphorus  
[IP_ADDRESS]  Induction Day 5  
• CBC with differential  
• Chemistry profile (ALT, AST, alkaline phosphatase,  total bilirubin, calcium, bicarbonate, 
sodium, potassium, chloride, creatinine, BUN, total protein and albumin)  
• LDH, uric acid, magnesium, phosphorus  
• Study drug administration (initiation of CPX -351 intravenously)  
[IP_ADDRESS]  Induction Day 6  
• CBC with differe ntial  
• Chemistry profile (ALT, AST, alkaline phosphatase, total bilirubin, calcium, bicarbonate, sodium, potassium, chloride, creatinine, BUN, total protein and albumin)  
• LDH, uric acid, magnesium, phosphorus  
 
[IP_ADDRESS]  Induction Day 7  
• CBC with differential  
LI S T  O F  A B B R E VI A TI O N S  Pr ot oc ol Titl e: C P X -3 5 1 f or R el a ps e d/ R efr act or y ALL                                                                                           Pr ot oc ol V. 3. 0                                                              
Pr ot oc ol #: 1 9 4 8 2                                                                                                                                                             1 1 D ec 2 0 1 9     
 1 7  1 2 1 2 3  • C h e mistr y pr ofil e ( AL T, A S T, al k ali n e p h os p h at as e, t ot al bilir u bi n, c alci u m, bic ar b o n at e, 
s o di u m, p ot assi u m, c hl ori d e, cr e ati ni n e, B U N, t ot al pr ot ei n a n d al b u mi n)  
• L D H, uric aci d, m a g n esi u m, p h os p h or us  
• P eri p h er al bl o o d s a m pl e f or c orr el ativ e st u di es  
• C S F s a m pl e/I T c h e m o ( if n o c o ntr ai n dic ati o ns, will  b e p erf or m e d d ay 7 -1 0  s e e S ecti o n 
7. 1. 1 5)  
7. 3. 2. 8  I n d ucti o n D a y 1 0  
• C B C wit h diff er e nti al  
• C h e mistr y pr ofil e ( AL T, A S T, al k ali n e p h os p h at as e, t ot al bilir u bi n, c alci u m, bic ar b o n at e, 
s o di u m, p ot assi u m, c hl ori d e, cr e ati ni n e, B U N, t ot al pr ot ei n a n d al b u mi n)  
• L D H, uric aci d, m a g n esi u m, p h os p h or us  
• C S F s a m pl e/I T c h e m o (if n ot p erf or m e d o n d a y 7, 8, or 9)  
• C o nti n u o us h os pit aliz ati o n u ntil d et er mi n e d t o h av e acc e pt a bl e b o n e m arr o w r ec o v er y  
7. 3. 2. 9  I n d ucti o n D a y 2 8  
• C B C wit h diff er e nti al  
• C h e mistr y pr ofil e ( AL T, A S T, al k ali n e p h os p h at as e, t ot al bilir u bi n, c alci u m, bic ar b o n at e, 
s o di u m, p ot assi u m, c hl ori d e, cr e ati ni n e, B U N, t ot al pr ot ei n a n d al b u mi n)  
• L D H, uric aci d, m a g n esi u m, p h os p h or us  
• B o n e m arr o w bi o psy , if b o n e m arr o w bi o psy is p ositiv e at scr e e ni n g  
• C T or  P E T/ C T  sc a n of  aff ect e d  ar e as  f or  r es p o ns e  ass ess m e nt  f or  s u bj ects  wit h  
extr a m e d ull ar y dis e as e  
• P eri p h er al bl o o d s a m pl e f or c orr el ativ e st u di es  
7. 3. 2. 1 0  I n d ucti o n D a y 2 9 +  
• C o nti n u o us h os pit aliz ati o n u ntil d et er mi n e d t o  h av e acc e pt a bl e b o n e m arr o w r ec o v er y  
• L a b or at ory t esti n g c o nti n u es p er st a n d ar d of c ar e u ntil h os pit al disc h ar g e  
7. 3. 2. [ADDRESS_851163] C o ns oli d ati o n T h er a p y  D a y 1  
• S u bj ect h as d oc u m e nt e d r es p o ns e  (C R , Cri , or P R, s e e A p p e n dix A), or i n t h e o pi [INVESTIGATOR_9384] o n of 
t h e pri nci p al i nv esti g at or is s h o wi n g cli nic al b e n efit  wit h a d e q u at e c o u nt r ec ov ery ( A N C > 
5 0 0/ L  a n d plat e le t s > 5 0, 0 0 0/   L).  
• C B C wit h diff er e nti al  
LI S T  O F  A B B R E VI A TI O N S  Pr ot oc ol Titl e: C P X -3 5 1 f or R el a ps e d/ R efr act or y ALL                                                                                           Pr ot oc ol V. 3. 0                                                              
Pr ot oc ol #: 1 9 4 8 2                                                                                                                                                             1 1 D ec 2 0 1 9     
 1 8  1 2 1 2 3  • C h e mistr y pr ofil e ( AL T, A S T, al k ali n e p h os p h at as e, t ot al bilir u bi n, c alci u m, bic ar b o n at e, 
s o di u m, p ot assi u m, c hl ori d e, cr e ati ni n e, B U N, t ot al pr ot ei n a n d al b u mi n)  
• D a y [ADDRESS_851164] art of i n d ucti o n  
• St u dy dr u g a d mi nistr ati o n (i niti ati o n of C P X -3 5 1 i ntr av e n o usl y)  
7. 3. 2. [ADDRESS_851165] C o ns oli d ati o n T h er a p y D a y 3  
• C B C wit h diff er e nti al  
• C h e mistr y pr ofil e ( AL T, A S T, al k ali n e p h os p h at as e, t ot al bilir u bi n, c alci u m, bic ar b o n at e, 
s o di u m, p ot assi u m, c hl ori d e, cr e ati ni n e, B U N, t ot al pr ot ei n a n d al b u mi n)  
• St u dy dr u g a d mi nistr ati o n (i niti ati o n of C P X -3 5 1 i ntr av e n o usl y)  
7. 3. 2. [ADDRESS_851166] C o ns oli d ati o n D a y 2 8  
• C B C  wit h diff er e nti al  
• C h e mistr y pr ofil e ( AL T, A S T, al k ali n e p h os p h at as e, t ot al bilir u bi n, c alci u m, bic ar b o n at e, 
s o di u m, p ot assi u m, c hl ori d e, cr e ati ni n e, B U N, t ot al pr ot ei n a n d al b u mi n)  
• L D H, uric aci d, m a g n esi u m, p h os p h or us  
• B o n e m arr o w bi o psy , if b o n e m arr o w bi o psy is p ositiv e at scr e e ni n g  
• C T or P E T/ C T sc a n of aff ect e d ar e as t o ass ess  r es p o ns e f or s u bj ects wit h extr a m e d ull ar y 
dis e as e  
7. 3. 2. 1 4 S ec o n d,  a n d  T hir d C o ns oli d ati o n T h er a p y D a y 1  
• S u bj ect h as d oc u m e nt e d r es p o ns e  (C R ,C Ri , or P R,  s e e A p p e n dix A), or i n t h e o pi [INVESTIGATOR_9384] o n of 
t h e pri nci p al  i nv esti g at or is d e m o nstr ati n g  cli nic al b e n efit  wit h a d e q u at e c o u nt r ec ov ery 
( A N C > 5 0 0/ L  a n d plat elets > 5 0, 0 0 0/  L)  
• C B C wit h diff er e nti al  
• C h e mistr y pr ofil e ( AL T, A S T, al k ali n e p h os p h at as e, t ot al bilir u bi n, c alci u m, bic ar b o n at e, 
s o di u m, p ot assi u m, c hl ori d e, cr e ati ni n e, B U N, t ot al pr ot ei n a n d al b u mi n)  
• Ec h oc ar di o gr a m  will  b e  r e p e at e d  f or  a ny  p ati e nt  wit h  > 5 5 0 m g/ m 2  d a u n or u bici n  ( or  
d a u n or u bici n  a nt hr ac ycli n e e q ui v al e nt) ex p os ur e.  T h er a py will o nl y b e p er mitt e d if t h e 
ej ecti o n fr acti o n r e m ai ns > 5 0 %  a n d wit h o ut > 1 0 % d ecr e as e i n ej ecti o n fr acti o n fr o m 
b as eli n e.  
• D a y [ADDRESS_851167] art of t h e pr e vi o us c o ns oli d ati o n  
• St u dy dr u g a d mi nistr ati o n (i niti ati o n of C P X -3 5 1 i ntr av e n o usl y)  
7. 3. 2. [ADDRESS_851168]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 19 [ZIP_CODE]  • CBC with differential  
• Chemistry profile (ALT, AST, alkaline phosphatase, total bilirubin, calcium, bicarbonate, 
sodium, potassium, chloride, creatinine, BUN, total protein and albumin)  
• Study drug administration (initiation of CPX -351 intravenously)  
7.32.[ADDRESS_851169] Consolidation Day 28  
• CBC with differential  
• Chemistry profile (ALT, AST, alkaline phosphatase, total bilirubin, calcium, bicarbonate, 
sodium, potassium, chloride, creatinine, BUN, total protein and albumin)  
• LDH, uric acid, magnesium, phosphorus  
• Bone marrow biopsy , if bone marrow biopsy is positive at screening  
• CT or PET/CT scan of affected areas to assess response for subjects with extramedullary 
disease  
[IP_ADDRESS]   End of Treatment Visit  
• Visit occurs 30 days (+10 days) after the last dose of study drug  
• May occur earlier if initiating subsequent antineoplastic therapy  
• Assess adverse events  
 
 
After the end of treatment assessment, a ll subjects will be followed with procedures  and physical 
examinations per standard of care.  
 
 
When it is determined the study is to be final closed, a Final Study Visit will be performed. This visit will 
occur at the next regularly scheduled standard of care Follow -Up Visit after trial closure is confirmed. 
Any AE that is ongoing will be considered  ongoing at the Final Study Visit.  
 Final instructions will be provided to the subject and the subject will be informed if results will be available or any planned presentation or publication of study data.   
 
 
If a subject terminates study participation for any reason prior to completion of the protocol treatment plan, 
any subsequent procedures or evaluations will be per physician discretion as part of standard of care. Evaluation of AEs will continue as outlined in Section 7.1.9.  
 
 
Any visit  not included on the Schedule of Events Table that includes examination in the Moffitt 
hematology clinic, inpatient hospi[INVESTIGATOR_636634], laboratory 
7.3.[ADDRESS_851170]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851171]’s medical record and included on the adverse event log. Adverse event or 
serious adverse event data will be collected in Oncore. No separate Oncore form for an unscheduled 
visit will be used to collect additional data.  
 
 
     
Procedures:                                         
Day:  Screeninga 1 2 3 4 5 6 7 10 28 29+i End of  
Treatment/  
Early 
Term.g Follow -
Up 
Informed consent  X             
Demographics and  
Medical History  X           
  
Baseline Symptomsb  X            
day Performance Status  X          
Concomitant Medication 
Review  X Assess throughout Induction and 
Consolidation    
Review Adverse Eventsc 
 Assess throughout Induction and 
Consolidation  X  
CPX-351 Administrationd  X  X  X        
Physical Examination  X             
Serum pregnancy teste X             
Vital signs (temp, pulse, resp, 
BP, weight)  X X  X  X Per SOC  
Height  X             
12-lead EKG  X             
Echocardiography/MUGA  X          Xl   
CBC with differential  X X X X X X X X X X Per SOC  
Serum chemistry testing f X X X X X X X X X X Per SOC  
LDH, uric acid, magnesium, 
phosphorus  X X X X X X X X As needed  
  
Coagulation studies  
(PT/INR, aPTT, fibrinogen)  X           
  
Urinalysis with microscopy  X             
Bone marrow biopsyk X         X    
CT or PET/CT  Scanm X         X    
Correlative studiesh       X1,2,3         X3    
CSF for ALL involvement/IT 
chemoj X       X   
  
Follow -Up             X 
 
a. Screening assessments will be performed within [ADDRESS_851172] of care 
procedure performed within 28 days of Day 1, may be used for screening/eligibility even if performed prior to 
consent.  
b. Baseline symptoms are defined as those present at the closest time before the start of study drug administration.  
c. Adverse event data will be captured from the time of consent  until [ADDRESS_851173]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851174] will be performed on females of chi ldbearing potential (FCBP). A FCBP is considered 
when a sexually mature female: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not 
been naturally postmenopausal for at least 12 consecutive months.    
f. Serum chemistry testing will i nclude the following: albumin, BUN, creatinine, alkaline phosphatase, ALT, AST, 
CO2, calcium, chloride, glucose, potassium, sodium, total bilirubin, total protein.  
g. The EOT visit will occur 30 days (+10 days) after the last dose of study drug or before the  start of subsequent 
antineoplastic therapy if that occurs sooner.  
h. Correlative studies will be performed as below:  
1. BH3 protein - bone marrow /core biopsy  
2. Ex vivo drug sensitivity assay - bone marrow /core biopsy  
3. T-cell profile - bone marrow /core biopsy/peripheral blood  
4. PDL1 immunohistochemistry - bone marrow /core biopsy  
i. After induction day [ADDRESS_851175] of care, CSF (if no contraindications ) will be obtained 
7-10 days after initiation of CPX dosing and IT methotrexate will be administered. See Section 7.1.15.  
k. Bone marrow biopsy will be at screening and day 28 of induction therapy. During consolidation therapy, a bone marrow biopsy will be performed on day 28 (+7 days) after the start of each consolidation per standard of care.  
l. Echocardiogram will be repeated for any patient with >550mg/m2 daunorubicin (or daunorubicin anthracycline equivalent) e xposure.  Therapy will only be permitted if the ejection fraction remains >50% and without >10% 
decrease in ejection fraction from baseline . 
m. CT or PET/CT scan will be utilized at screening and Day [ADDRESS_851176] to notify the study staff about any new medications he/she 
takes after the start of the study drug. All medications (other than study drug) and significant non -drug 
therapi[INVESTIGATOR_014]  (including physical therapy and blood transfusions) administered after the subject starts 
treatment with study drug must be recorded:  
 
• Administration of pegfilgrastim or filgrastim following initiation of protocol therapy will occur for all 
patients.  It is suggested dosing start at Day 6.  
• Administration of erythropoietin or darbopoietin is allowed;  
• Patients must be instructed not to take any additional medications (including herbal supplements and over -the-counter products) during the trial without p rior consultation with the investigator. All 
medications taken within [ADDRESS_851177] be added or changed, the reason and name [CONTACT_18467]/therapy should be recorded;  
• In general, the use of any concomitant medication/therapi[INVESTIGATOR_636635], including drugs given prophylactically  (e.g. antiemetics ). 
 
 
7.[ADDRESS_851178]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 22 [ZIP_CODE]   
 
• Subjects will not routinely be pre -medicated for hypersensitivity or infusion- related reactions initially 
during the first infusion of the first treatment course. If a reaction occurs, pre -medications for 
subsequent infusions will be at investigator discretion. Infusion reactions will be treated per Moffitt 
institutional standards.  
• In previous clinical trials, n o drug or food interactions were  identified as being associated with CPX -
351. 
 
 
• An evaluation of prior exposure to anthracyclines should be performed during screening. Per the study Exclusion Criteria, subjects with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin will be excluded.  
• High dose c orticosteroi ds used for management of ALL symptoms are permitted up to one day 
prior to the first dose of study drug. Corticosteroids required as pre -medication for CT scans or for 
short -term use as treatment for adverse events, are permitted in consultation with the PI.  
• Other anti -cancer treatment is not permitted during the treatment phase of the study.  
 
 
• Subjects may be pre -medicated for nausea and vomiting at investigator discretion.  
• Patients may receive ongoing supportive and palliative care (e.g. pain control) as clinically 
indicated throughout the study.  
• Prophylactic use of anti-infectives is highly recommended during the period of profound 
neutropenia until ANC returns to 500/μL or greater. The choice of anti-infectives will be per Moffitt 
institutional standard of care.  
• Growth factor support will be administered according to Moffitt protocol. 
• The use of transfusion support (RBCs and platelets) will be according to standard of care . 
 
 
• Growth factor support  with granulocyte stimulating factor will be administered according to 
Moffitt protocol for the treatment of cytopenias  
• The use of transfusion support (RBCs and platelets) will be according to standard of care as rescue therapy for anemia or thrombocytopenia. 
• Corticosteroids  and antihistamines may be administered per Moffitt protocol for the treatment of 
hypersensitivity reactions should they emerge.  
 
 
 
 
 
 
An adverse  event  means  any untoward medical  occurrence  associated  with  the use of an intervention  in 
humans,  whether  or not considered  intervention -related  (21 CFR 312.32  (a)). 
 
The investigator or qualified designee will assess each subject to evaluate for potential new or worsening AEs as specified in the Schedule of Events and more frequently if clinically indicated.  Adverse experiences will be graded and recorded throu ghout the study and during the follow -up 
7.5.1  PRECAUTIONARY  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  
7.6 PROHIBITED  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  
7.7 PROPHYLACTIC  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  
7.8 RESCUE  MEDI CATIONS,  TREATMENTS,  AND  PROCEDURES  
8 ASSESSMENT  OF SAFETY  
8.1 SPECIFICATION  OF SAFETY  PARAMETERS  
8.1.1  DEFINITION  OF ADVERSE  EVENTS  (AE)  
LIST  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 23 [ZIP_CODE]  period. The descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 5.0  will be utilized for adverse event reporting. 
(http://ctep.cancer.gov/reporting/ctc.html)  
Toxicities will be characterized in terms regarding seriousness, causality, toxicity grading, and action taken with regard to trial treatment.  
 
 
Adverse events  and suspected adverse  reactions are  considered  "serious"  if, in the view  of either  the 
investigator  or sponsor,  they result  in any  of the following  outcomes: death,  a life-threatening adverse 
event,  inpatient  hospi[INVESTIGATOR_40088],  a persistent  or significant  
incapacity or  substantial disruption of  the ability  to conduct  normal  life functions,  or a congenital  
anomaly/birth defect.  Important  medical  events  that may  not result  in death,  be life-threatening,  or 
require  hospi[INVESTIGATOR_353365],  based  upon appropriate  medical judgment, 
they may  jeopardize  the patient  or subject and may  require  medical  or surgical intervention to  prevent  
one of the outcomes  listed  in this definition.   
 
 
 
Unanticipated problems (UPs)  involving  risks  to participants  or others  to include,  in general,  any 
incident,  experience,  or outcome  that meets  all of the following  criteria:  
 
• Unexpected  in terms  of nature,  severity,  or frequency  given (a) the research procedures  that are 
described  in the protocol -related documents,  such as the IRB-approved  research  protocol  and 
informed  consent  document;  and (b) the characteristics  of the participant  population being  
studied;  
• Related  or possibly  related  to participation  in the research (“possibly  related”  means  there is a 
reasonable  possibility  that the incident,  experience,  or outcome  may  have  been  caused  by [CONTACT_544233]);  and 
• Suggests  that the research  places  participants  or others  at a greater  risk of harm (including 
physical,  psychological,  economic,  or social harm)  than  was previously  known or recognized.   
 
 
 
 
 
 
All AEs will be graded using the CTCAE 5.0 criteria.  
 For AEs not included  in the protocol -defined grading  system,  the following  guidelines  will be used  to 
describe  severity.  
 
• Mild  – Events  require  minimal  or no treatment  and do  not interfere  with  the participant’s  daily  
activities.  
• Moderate – Events  result in a low level  of inconvenience  or concern  with the therapeutic  
measures.  Moderate  events  may  cause  some  interference  with  functioning. 
• Severe – Events  interrupt  a participant’s  usual  daily  activity  and may  require  systemic  drug 
therapy  or other  treatment.  Severe  events  are usually potentially  life-threatening or 
8.1.2  DEFINITION  OF SERIOUS  ADVERSE  EVENTS  (SAE)  
8.1.[ADDRESS_851179]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 24 [ZIP_CODE]  incapacitating.  
 
 
For all collected AEs, the investigator will evaluate  the participant  and will determine  the AE’s causality  
based  on temporal  relationship and his/her  clinical  judgment.  The degree  of certainty  about  causality 
will be graded using  the categories  below.  
 
 
• Definitely  Related – There is clear evidence  to suggest a causal relationship,  and other possible  
contributing factors  can be ruled out.  The clinical  event,  including an abnormal laboratory  test 
result,  occurs  in a plausible  time  relationship  to drug administration and  cannot  be explained  by 
[CONTACT_636662]. The response  to withdrawal  of the drug  
(dechallenge)  should be clinically  plausible. The  event  must  be pharmacologically  or 
phenomenologically  definitive,  with use of a satisfactory  rechallenge  procedure  if necessary. 
• Probably  Related  – There  is evidence  to suggest  a causal  relationship,  and the influence  of other  
factors  is unlikely.  The clinical  event, including an abnormal  laboratory  test result,  occurs  within  
a reasonable  time after  administration  of the drug,  is unlikely  to be attributed  to concurrent 
disease  or other  drugs  or chemicals,  and follows  a clinically  reasonable  response  on withdrawal  
(dechallenge).  Rechallenge  information is  not required  to fulfill this  definition.  
• Possibly  Related  – There  is some evidence  to suggest a causal relationship (e.g.,  the event  
occurred  within  a reasonable  time  after  administration of the trial medication). However,  other  
factors  may  have  contributed  to the event (e.g.,  the participant’s  clinical  condition,  other  
concomitant  events). Although an  AE may  rate only  as “possibly  related”  soon after  discovery,  it 
can be flagged  as requiring more information  and later  be upgraded to “probably  related”  or 
“definitely related,”  as appropriate.  
• Unlikely  to be rel ated  – A clinical event, including an abnormal  laboratory  test result, whose  
temporal relationship to  drug  administration  makes  a causal  relationship improbable  (e.g.,  the 
event  did not occur  within  a reasonable  time  after administration  of the trial medication)  and in 
which  other  drugs  or chemicals  or underlying disease provides  plausible  explanations  (e.g.,  the 
participant’s  clinical condition,  other  concomitant  treatments).  
• Unrelated – The AE is  completely  independent  of study  drug administration,  and/or  evidence  
exists  that the event  is definitely  related  to another  etiology.  There must  be an alternative,  
definitive  etiology  documented by [CONTACT_15370]. 
 
 
 
The PI [INVESTIGATOR_636636].  An AE will be 
considered unexpected  if the nature,  severity,  or frequency  of the event  is not consistent  with the risk 
information previously  described  for the study  agent.  
 
 
The occurrence  of an AE or SAE may  come  to the attention  of study  personnel  during study  visits  and 
interviews  with  study participants  presenting for  medical care,  or upon review  by a study  monitor. All 
AEs, including local  and systemic  reactions not  meeting the criteria for SAEs,  will be captured  on the 
appropriate CRF. Information to  be collected includes  event  description,  time  of onset,  clinician’s  
assessment of severity, relationship to  study product  (assessed only by  [CONTACT_636663] a diagnosis), and  time  of resolution/stabilization of  event.  All AEs occurring during 
the study  must be documented appropriately,  regardless of relationship. All AEs  will be followed to  
adequate resolution.  
8.2.[ADDRESS_851180]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 25 [ZIP_CODE]   
Any medical  condition that  is present  at the time  that the participant is screened  will be considered  as 
baseline  and not  reported as an AE.  However,  if the study  participant’s  condition  deteriorates  at 
anytime  during the  study,  it will be  recorded  as an AE.  UPs will be recorded  in the data  collection system  
throughout  the study.  
 
Changes  in the severity  of AEs will be documented to  allow  an assessment  of the duration  of the event  
at each  level  of severity  to be  performed. AEs characterized  as “intermittent”  require  documentation of 
onset  and duration of each  epi[INVESTIGATOR_636637].  
 
Adverse events for the purpose of this study will be will be reported from the time period beginning 
when the consent form is signed until [ADDRESS_851181].   
 
All AEs will be documented on a paper log with columns for the replication of the fields in the OnCore  
AE data form. The treating physician/investigator will review the log for accuracy and assign CTCAE grade and the attribution of a study agent to the AE.   Adverse events for the purpose of this study will be reported from the time period beginning when t he 
consent form is signed until 30 days after study drug discontinuation.  
 
 
 
All SAEs  will be followed  until  satisfactory  resolution  or until  the site investigator deems  the event  to be 
chronic  or the adherence  to be stable.  Other  supporting documentation  of the event  may  be requested  
by [CONTACT_156239], Inc.  and should be  provided  as soon  as possible.  Moffitt as the study sponsor  
will be responsible  for notifying FDA  of any unexpected  fatal or life-threatening  suspected  adverse  
reaction  as soon as  possible  but in no case  later  than  7 calendar  days  after  the sponsor's  initial receipt  
of the information.  
 
 
 
Incidents  or events  that meet  the OHRP criteria for UPs require  the creation and completion  of an  UP 
report  form.  It is the site investigator’s  responsibility  to report  UPs to their IRB and to Jazz 
Pharmaceuticals, Inc . The UP report  will include  the following  information:  
 
• Prot
ocol identifying information:  protocol  title and number,  PI’s name,  and the  IRB project  
number;  
• A detailed  description of the event,  incident,  experience,  or outcome; 
8.[ADDRESS_851182]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 26 [ZIP_CODE]  • An explanation  of the basis  for determining that  the event,  incident,  experience,  or outcome  
represents  an UP; 
• A description of any changes  to the protocol  or other  corrective actions  that have  been  taken  or 
are proposed  in response  to the UP. 
 
To satisfy  the requirement  for prompt  reporting,  UPs will be reported  using the  following  timeline:  
 
• UPs that are SAEs  will be reported  to the IRB and to the study  sponsor within  24 hours  of 
the investigator  becoming aware  of the event.  
• Any other  UP will be reported  to the  IRB and  to the study  sponsor  within  2 business days of the 
investigator  becoming  aware of the problem.  
• All UPs should be reported  to appropriate  institutional  officials  (as required by [CONTACT_17347]’s  
written  reporting procedures) and the supporting agency  head (or designee),  within 7 days  of 
the IRB’s  receipt  of the report  of the problem  from  the investigator.  
 
 
 
1. Cardiotoxicity: Current studies estimate the risk of cardiotoxicity to be low, perhaps related to the 
liposomal formulation.  However, given that patients will have likely had prior anthracycline exposure (up to a maximum of 368 mg/m2 daunorubicin or equiv alent), we will obtain baseline echocardiogram 
or MUGA to ensure adequate ejection fraction.  Followup echocardiogram or MUGA will be performed in all patients with symptomatic heart failure , defined as follows:  worsening 1) dyspnea on exertion, 2) 
orthopn ea, and/or 3) paroxysmal nocturnal dyspnea - with following concomitant findings of fluid 
overload on exam not well explained by [CONTACT_636664] (such as hydration related to an epi[INVESTIGATOR_636638]), including: 1) development of a third heart sound, 2) jugular  venous distention with positive 
hepatojugular reflex,  3) pulmonary rales, and/or 4) lower extremity edema  (ref 31) .  Follow -up 
echocardiogram or MUGA prior to each cycle of consolidation will be performed  for all patients 
exceeding 550 mg/m2 daunorubicin  (or equivalent) .  Patients with an ejection fraction of <50% or a 
decrease of >10% from baseline  will discontinue consolidation therapy. The development of 
symptomatic heart failure and/or decrease in ejection fraction  to <50%, or  >10%  from baseline  will be 
reported to Jazz Pharmaceuticals . 
 
2. Bone marrow aplasia: Liposomal delivery of chemotherapy may facilitate increased deposition within hematopoietic stem cells, culminating in delay or failure to recover hematopoietic cell reconstitution following therapy.  In particular, a hypocellular marrow without adequate count recovery >[ADDRESS_851183]. Information regarding the pregnancy and/o r the outcome may be requested by [CONTACT_636665].  
 
In addition to reporting any pregnancies occurring during the study, investigators will monitor for 
pregnancies that occur after the last dose of CPX -[ADDRESS_851184]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851185] of monitoring and recording all adverse events and serious adverse 
events, the regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and 
tolerability will be assessed according to the NIH/NCI Common Terminology Criteria for Adverse Events version (CTCAE v 5.0) that is available at: http://evs.nci.nih.gov/ftp1/CTCA E/About.html
 
The Protocol Monitoring Committee (PMC) at Moffitt monitors its assigned ongoing research protocols for: adverse event reporting, data and safety monitoring, and internal audit findings. The PMC, upon review of any agenda item, may approve the  study for continuation, require revisions, suspend or close 
a protocol.   The PMC meets monthly and reviews accrual, patterns and frequencies of all adverse 
events, protocol violations and when applicable, internal audit results.  
 Investigators of studies which are designated to be reviewed by [CONTACT_636666],  shall provide a statistical report of the study’s progress and summary of adverse events and deviations based on the phase of the study and the associated risk of the study or more often if applicable. The PI [INVESTIGATOR_636639].  
 
 
 
 
Serious Adverse Events: Serious Adverse Events (SAEs) from this protocol will be reported concurrently to the IRB (per IRB guidelines) and Jazz Pharmaceuticals, Inc.  within 24 hours of staff awareness of the 
event. The Protocol Monitoring Committee (PMC) will review these SAEs in accordance with their policy. The data and safety plan will define dose limiting toxicities and criteria for stoppi[INVESTIGATOR_636640]. This trial will be continuously monitored by [CONTACT_978] [INVESTIGATOR_44200]. A final safety and monitoring report will be submitted to the PMC. This protocol will be subject to periodic internal audits based on risk or as recommended by [CONTACT_428360].  
 
 
 
Data will be captured in OnCore, Moffitt ’s electronic Clinical Trials Database. For each participant 
enrolled, the electronic CRF must be completed by [CONTACT_636667]. Any paper forms should be typed or filled out indelible ink and must be legible. Error s 
should be crossed out but not obliterated, the correction inserted, and the change initialed and dated by [CONTACT_15009]/her authorized delegate. This also applies to records for those patients who fail to complete the study. If a patient stops dosing or terminates from the study, the dates and reasons must be noted on the CRF. If a patient terminates from the study because of a DLT, thorough efforts should be made to clearly document the outcome.   Regulatory documents and case report forms will be monitored internally according to Moffitt Cancer 
Center Monitoring Policies. Monitoring will be performed regularly by [CONTACT_636668] 
8.[ADDRESS_851186]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 28 [ZIP_CODE]  Core for accuracy, completeness, and source verification of data entry, validation of appropriate 
informe d consent process, reporting of SAEs, adherence to the protocol, Good Clinical Practice (GCP) 
guidelines, and applicable regulatory requirements.  
 
 
 
 
 
The following study is a  phase 2  pi[INVESTIGATOR_4251].  Exploratory analyses of remission rate, safety, progression free 
survival, and overall survival are planned.  
 
 
• All Endpoints are exploratory, and may be used to facilitate design of an expansion or subsequent phase 2 study.  
• Primary  Efficacy  Endpoint:  
• Complete Remission and Complete Remission with incomplete hematologic recovery will serve as the primary endpoint.   
• Secondary  Efficacy  Endpoint(s):  
• Safety  
• Minimal Residual Disease Remission Rate  
• Progression Free Survival 
• Overall Survival 
 
• All patients receiving at least one dose of CPX -351will be evaluable for safety.   
• Efficacy analyses will be restricted to those receiving a full cycle of induction therapy.  
 
 
 
This will be a  phase 2  pi[INVESTIGATOR_636641] -351 in relapsed and refractory acute 
lymphoblastic leukemia. If 4 or more CR/CRi are  observed in the first 10 patients, Jazz Pharmaceuticals 
will consider an increase  in the budget to facilitate accrual to a total of 19  patients  (ie, 9 additional 
subjects) , possibly in a multi -center setting.  This would be sufficient to test our hypothesis that CPX -
351 will increase the CR/CRi rate from a historical standard of 35% to 65% (as summarized in section 2.2) using a power of 90% and type I error rate of 0.1.  
 
 
As noted above, this is a  phase 2  pi[INVESTIGATOR_4251].  However, expansion to a phase II trial will depend on 
demonstration of CR/CRi  amongst  [ADDRESS_851187] 
provided Simon Two -Stage Calculation, using power of 90% and Type I error rat e of 0.1.    
 
 
 
   N1 R1 PET N R Ave N  Alpha  Beta  
10 3 0.514  19 9 14.38  0.084  0.095  
10 STATISTICAL  CONSIDERATIONS  
10.1  STATISTICAL  AND  ANALYTICAL  PLANS  
10.2  STATISTICAL  HYPOTHESES  
10.3  ANALYSIS  DATASETS  
10.4  DESCRIPTION  OF STATISTICAL  METHODS  
10.4.1  GENERAL  APPROACH  
10.4.2  ANALYSIS  OF THE  PRIMARY  EFFICACY  ENDPOINT(S)  
LIST  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851188] 6 patients over a 12 month interval.   
 
 
 
• Minimal Residual Disease (MRD) will be studied as a dichotomous endpoint using a cutoff of 1x10-4 
cells/transcripts as the lower limit for residual leukemia, and presented as the percentage of 
patients reaching this landmark as their best response.   MRD assessment will be obtained with each 
bone marrow biopsy assessment, as described below.  
• Progressio n Free Survival and Overall Survival will be reported as per Cheson and Lugano Criteria, 
and analyzed using a standard Kaplan -Meier approach.  Patients will undergo bone marrow biopsy 
evaluation after each cycle of therapy per standard of care to facilitat ed assessment.  Patients 
achieving CR/CRi at the end of consolidation  with marrow involvement  will have follow -up bone 
marrow biopsy evaluation every [ADDRESS_851189] follow -up 
imaging (CT or PET/CT) every [ADDRESS_851190] cycle. Patients progressing to 
allogeneic transplant following therapy will be censored at the time of conditioning.   
• Safety will be continually assessed during the course of induction and consolidation cycles.  Safety assessment will continue at a minimum of every 3 months for those who do not progress to 
allogeneic transplant or alternative therapy.  
 
 
Using summary statistics, s afety data will be coded using CTCAE 5.0  criteria, with each AE being  counted 
only once for a given participant.  The severity, frequency, duration, outcome, and relationship of  AEs to 
study  agent, as defined by [CONTACT_12707],  will be presented by  [CONTACT_79075]  (SOC) and 
preferred  term  groupi[INVESTIGATOR_14839].  Adverse  events  leading to premature  discontinuation from  the study  drug, 
adverse events of special interest, and serious  treatment -emergent AEs  will be  presented in a table .   
 
 
Patients will be hospi[INVESTIGATOR_636642] , and remain so until sufficient recovery permits 
safe hospi[INVESTIGATOR_2345], in accordance with standard of care.  Consolidation therapy will be administered as an outpatient.  Patients will be monitored as an outpatient in accordance with s tandard of care until 
recovery  or study discontinuation.    Study discontinuation due to adverse events, related or unrelated to 
study drug, will be assessed.  
 
 
Planned baseline statistics include age, ethnicity, gender, genetic risk group (Philadelphia positive, Philadelphia -like, MLL rearranged, p53 mutant, etc…), baseline marrow blast burden, number of prior 
therapi[INVESTIGATOR_014], response to prior therapi[INVESTIGATOR_014] (i.e., relapsed  vs refractory) , and prior exposure to s elected 
therapeutic modalities (including allogeneic transplant, CAR T -cell therapy, blinatumomab, and 
inotuzumab) .  Demographics will be presented using summary statistics.  
 
 
Responses will be presented in aggregate only.  
 
10.4.3  ANALYSIS  OF THE  SECONDARY  ENDPOINT(S)  
10.4.[ADDRESS_851191]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 30 [ZIP_CODE]  
10.6.1  ENROLLMENT   
As previously noted, all endpoints are presently exploratory in nature, and may be used to support 
expansion of the present study, and/or development of a separate study.  
 
 
Moffitt is a high volume center for ALL, with approximately 50 new cases referred to our center yearly, 
of whom ~10% are anticipated to be refractory to therapy, and ~50% will relapse within 2 years of 
therapy.  The current inclusion and exclusion criteria  developed within this protocol, as well as prior 
enrollment to protocols targeting ALL, support a screen failure rate of less than 10%. Similarly, internal 
experience  with CPX-351 supports a drop -out rate (ie, failure to complete induction) of less than 10%.  
Accordingly, we anticipate full accrual of [ADDRESS_851192] charts (with paper AE logs), research laboratory notes, electronic CRFs, and pharmacy dispensing
 records.   
 
 
 
Quality control procedures  will be implemented beginning with  the OnCore data  entry system  and data  
QC checks  that will be run on the database  will be generated.  Any missing data  or data  anomalies  will 
be communicated  to the staff for clarification/resolution.  
 
Following  written  SOPs,  the Moffitt internal monitors  will verify  that the clinical trial is conducted and  
data  are generated,  documented  (recorded), and reported  in compliance  with  the protocol,  GCP,  and 
the applicable  regulatory  requirements  (e.g.,  good laboratory  practices  (GLP),  good manufacturing 
10.4.11  EXPLORATORY  ANALYSES  
 
10.5  SAMPLE  SIZE 
10.6  MEASURES  TO MINIMIZE  BIAS  
11 SOURCE  DOCUMENTS  AND  ACCESS TO SOURCE  DATA/DOCUMENTS  
[ADDRESS_851193]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 31 [ZIP_CODE]  practices  (GMP)).  
 
The investigational  site will provide  direct  access  to source  data/documents,  and reports  for the 
purpose  of monitoring and auditing,  and inspection by  [CONTACT_58700].  
 All staff will be trained by [CONTACT_978] [CONTACT_10782] a site initiation presentation, power point training for training 
on the initial protocol for those staff unable to attend the initiation presentation, and ongoing self -study 
as protocol amendments are approved. Training will be documented on a signature [CONTACT_636672].  
 
 
. 
 
 
The investigator  will ensure  that this study  is conducted  in full conformity  with  Regulations  for the 
Protection  of Human Subjects  of Research  codified  in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 
and/or  the ICH  E6. 
 
 
 
The protocol,  informed  consent  form(s),  recruitment  materials,  and all participant  materials  will be 
submitted  to the IRB for review  and approval.  Approval  of both the protocol  and the consent  form  must  
be obtained  before  any participant  is enrolled.  Any amendment  to the protocol  will require  review  and 
approval  by [CONTACT_564320].  All changes  to the consent form  
will be IRB approved;  a determination will be made  regarding whether  previously  consented  
participants  need to  be re-consented.  
 
 
 
13.3.1  CONSENT/ASSENT  AND  OTHER  INFORMATIONAL  DOCUMENTS  PROVIDED  TO PARTICIPANTS  
 
Consent  forms  describing in detail the study  agent,  study  procedures,  and risks  will be given  to the 
participant  and written  documentation of informed  consent  will be required prior to starting  
intervention/administering  study  product.  
 
 
 
Informed  consent  is a process  that is initiated prior  to the individual’s  agreeing to participate  in the  
study  and continues  throughout  the individual’s  study  participation.  Extensive  discussion  of risks  and 
possible  benefits  of participation will  be provided  to the participants  and their families.  Consent  forms  
will be IRB-approved  and the participant  will be asked  to read  and review  the document.  The 
investigator  will explain  the research study  to the participant  and answer  any questions  that may  arise.  
All participants  will receive  a verbal  explanation in terms  suited  to their  comprehension of the purposes,  
procedures,  and potential  risks  of the study  and of their  rights  as research  participants.   Participants  will 
have  the opportunity  to carefully  review  the written  consent  form  and ask questions  prior  to signing.  
 
The participants  should have  the opportunity  to discuss  the study  with their  surrogates  or think  about  it 
prior  to agreeing to  participate.  The participant  will sign the informed  consent document  prior  to any 
13 ETHICS/PROTECTION  OF HUMAN  SUBJECTS  
13.[ADDRESS_851194]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851195]  all documents  and records required  to 
be maintained  by [CONTACT_093],  including but  not limited  to, medical  records  (office,  clinic,  or 
hospi[INVESTIGATOR_307])  and pharmacy  records  for the participants  in this study.  The clinical study  site will permit  
access  to such records.  
 
The study  participant’s  contact  [CONTACT_636669].  At the end of the study,  all records  will continue  to be kept  in a secure  location for as 
long a period as dictated  by [CONTACT_262770]. 
 Stud
y participant  research  data,  which is for purposes  of statistical  analysis  and scientific  reporting,  will 
be transmitted  to and stored  at Moffitt.  This will not  include  the participants’  contact  [CONTACT_46203].  Rather,  individual participants  and their  research data  will be identified  by a unique  study  
identification number. The  study  data  entry  and study  management  systems  used  by [CONTACT_636670]. At  the end of the study,  all study  
databases  will be de-identified  and archived at  the Moffitt.  
 
 
  
Evaluation of correlative biomarkers will be performed on fresh tissue, with the exception of PLD1 immunohistochemis try.  Patients consenting to the TCC platform may have additional 
unused material archived for future use – however, this will occur outside the context of this 
protocol, and will be governed independently.   
 
A database will be created to store the clinical and analytical data for this project.  This 
database will be located on a password -protected hard drive, and additionally, the database 
will be itself password -protected to ensure maximal security with regards to maintained 
privacy of patient -related information.  Specific information included in this database will 
entail patient name, age, gender, medical record number, clinic al diagnosis, molecular 
phenotype, treatment history, and survival.  Database access will be limited to the PI [INVESTIGATOR_7706] -
PIs described above.  
 
Patients will be selected according to established inclusion criteria as identified above. 
Patients will be identifi ed primarily according to clinical documentation of disease status 
13.[ADDRESS_851196]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851197]; however, appropriate patients may 
also be identified in the context of clinical evaluation up front with names and medical 
record  numbers  referred to prior to scheduling the bone marrow biopsy procedure to 
facilitate sample identification and collection.  
 
 
Data collected for  this study  will be analyzed  and stored at the Moffitt Cancer Center. Permission to  
transmit  data  will be included  in the informed  consent. 
 
For patients consenting to the Moffitt Total Cancer Care (TCC) protocol, de-identified  biological samples  
will be stored  within the Moffitt TCC  biosample  repository  with  the same  goal as the sharing of data 
with  Jazz Pharmaceuticals . These samples  could be  used  for research into  the causes  of acute 
lymphoblastic leukemia , its complications  and other  conditions  for which  individuals  with  acute 
lymphoblastic leukemia are at increased  risk, and to  improve  treatment. The Moffitt TCC biosample 
repository will also  be provided  with a code -link that will allow  linking  the biological  specimens with  the 
phenotypic  data  from  each  participant,  maintaining the masking  of the identity  of the participant.  
 
During the  conduct  of the study,  an individual  participant  can choose  to withdraw  consent  to have  
biological specimens  stored for future  research.  However,  withdrawal of consent  with regard to  
biosample  storage  will not be possible  after  the study  is completed.  
 
When  the study  is completed,  access  to study  data  and/or  samples  will be provided  through the  Moffitt 
TCC repository.  
 
 
 
 
 
Data  collection is the responsibility  of the clinical trial staff  at the site under  the supervision of the site 
PI. The PI [INVESTIGATOR_636643],  completeness,  legibility,  and timeliness  of the data  
reported.  
 
All s
ource  documents  should be  completed in a neat,  legible  manner  to ensure  accurate  interpretation  
of data.  Black  ink is required  to ensure  clarity  of reproduced  copi[INVESTIGATOR_014]. When  making  changes  or 
corrections,  cross  out the original  entry  with a  single  line,  and initial and date  the change.   All paper 
source documents will be scanned into the electronic medical record of each subject for storage. DO  
NOT  ERASE,  OVERWRITE,  OR USE CORRECTION  FLUID  OR TAPE  ON THE ORIGINAL. 
 
Copi[INVESTIGATOR_262685] (eCRF) will be provided  for use as source  documents  and maintained  for 
recording data for each  participant  enrolled  in the study.  Data  reported  in the eCRF  derived  from  
source  documents  should be  consistent  with the source  documents  or the discrepancies  should be  
explained  and captured in a progress  note  and maintained  in the participant’s  official electronic  study  
record.  
 
Clinical data  (including AEs,  concomitant  medications,  and expected  adverse  reactions  data)  and clinical  
laboratory  data  will be entered into  OnCore , a [ADDRESS_851198]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851199]  elapsed  since the formal discontinuation  of clinical 
development  of the drug combination studied in this protocol . No records  will be destroyed  without  
the written  consent  of the sponsor,  if applicable.  
 
 
 
A protocol  deviation is any noncompliance  with  the clinical trial protocol,  GCP,  or MOP  requirements.  
The noncompliance  may  be either  on the part of the  participant,  the investigator,  or the study  site staff.  
As a result  of deviations,  corrective  actions  are to be developed by [CONTACT_58717]. 
 
These practices  are consistent with  ICH E6: 
• 4.5 Compliance  with  Protocol,  sections  4.5.1,  4.5.2,  and 4.5.3  
• 5.1 Quality  Assurance  and Quality  Control,  section  5.1.1  
• 5.[ADDRESS_851200]  be sent  to the local  IRB per their  guidelines. The site PI/study  staff 
is responsible  for knowing  and adhering to their IRB  requirements.  
 
 
 
The International  Committee  of Medical  Journal  Editors  (ICMJE) member  journals  have  adopted a clinical 
trials  registration  policy  as a condition for  publication. The ICMJE  defines  a clinical  trial as any research  
project  that prospectively  assigns  human subjects to intervention  or concurrent comparison  or control  
groups  to study  the cause -and-effect  relationship  between  a medical  intervention and a health  
outcome.  Medical  interventions  include  drugs,  surgical  procedures,  devices,  behavioral  treatments,  
process -of-care  changes,  and the  like. Health  outcomes  include  any biomedical  or health -related  
measures  obtained  in patients  or participants,  including pharmacokinetic  measures  and adverse  events.  
The ICMJE  policy,  and the Section [ADDRESS_851201]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ADDRESS_851202].  
 
 
 
1. Barba P, Sampol A, Calbacho M, et al. Clofarabine -based chemotherapy for relapsed/refractory adult  
acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. Am J Hematol . 
2012;87(6):631 –634.  
 
2. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and 
cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118(23):6043 –6049.  
 
3. Gökbuget N, Basara N, Baurmann H, et al. High single -drug activity of nelarabine in relapsed T -
lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118(13):3504 –3511.  
 
4. Weiss MA, Aliff TB, Tallman MS, et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer . 2002;95(3):581 –58
 
 
5. Tedeschi A, Montillo M, Strocchi E, et al. High -dose idarubicin in combination with Ara -C in patients 
with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother Pharmacol. 2007 May;59(6):771- 9. 
 
 
6. Giona F, Testi AM, Annino L, et al. Treatment of primary refractory and relapsed acute lymphoblast ic 
leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie 
Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia Pediatrica. Br J 
Haematol. 1994 Jan;86(1):55- [ADDRESS_851203];43(4):309 -13. 
 
8. Li X, Liu L, Zhang Y, et al. Efficacy of cytarabine, aclarubicin and granulocyte colo ny-stimulating factor 
(CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia 
chromosome -negative acute lymphoblastic leukemia. Leuk Res. 2015 Aug 28. pii: S0145 -
2126(15)[ZIP_CODE]- 0. 
 
9. Liu L, Jiao W, Zhang Y, et al. Efficacy of low -dose cytarabine and aclarubicin in combination with 
granulocyte colony -stimulating factor (CAG regimen) compared to Hyper- CVAD regimen as salvage 
chemotherapy in relapsed/refractory Philadelphia chromosome -negative acute lymphoblastic 
leukemia. Leuk Res. 2015 Mar;39(3):323-[ADDRESS_851204]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 36 [ZIP_CODE]  10. Ahn JS, Yang DH, Jung SH, et al. Clinical efficacy of mitoxantrone and Ara- C with or without etoposide 
salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: 
retrospective multicenter study of the Korean Adult ALL Working Party. Acta Haematol. 
2015;133(1):91- 7.  
 
11. O’Brien S, Schiller G, Lister J, et al. High -dose vincristine sulfate liposome injection for advanced, 
relapsed, and refractory adult Philadelphia chromosome -negative acute lymphoblastic leukemia. J 
Clin Oncol Off J Am Soc Clin Oncol. 2013;31(6):676 –68 
 
12. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute l ymphoblastic leukaemia: a multicentre, single -arm, phase 2 
study. Lancet Oncol. 2015 Jan;16(1):57- 66.  
 
13. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25;375(8):740- 53. 
 
14. Tafuri A, Gregorj C, Petrucci MT, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002;100:974 –
981.  
 
15. Pogorzala M, Kubicka M, Rafinska B, et al. D rug-resistance Profile in Multiple -relapsed Childhood 
Acute Lymphoblastic Leukemia. Anticancer Res. [ADDRESS_851205];35(10):5667 -70.  
 
16. Kourti M, Vavatsi N, Gombakis N, et al. Expression of multidrug resistance 1 (MDR1), multidrug resistance -related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance 
protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol. 2007 Aug;86(2):166- 73. 
 
17. Swerts K, De Moerloose B, Dhooge C, et al. Prognostic significance of  multidrug resistance -related 
proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer. 2006 Feb;42(3):[ADDRESS_851206];77(4):293-9 
 
19. Thomas D, O'Brien S, Faderl S, et al. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit  in the context of the fractionated cyclophosphamide, vincristine, 
doxorubicin, and dexamethasone regimen. Cancer. [ADDRESS_851207] 1;116(19):4580 -9.  
 
20. Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatl y enhances therapeutic efficacy. Leuk Res. 2009 Jan;33(1):129 -39 
 
21. Lim WS, Tardi PG, Dos Santos N, et al. Leukemia- selective uptake and cytotoxicity of CPX -351, a 
synergistic fixed -ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk R es. 
2010 Sep;34(9):1214- 23 
 
22. Tyner  JW, Tardi  P, Mayer  L, et al. Evaluation of CPX -351 (cytarabine:daunorubicin) Liposome Injection 
Anti-Leukemic Activity Against Primary Patient Leukemia Cells. Amer Soc of Hematol Ann Meeting, 
2010. Abstract #[ADDRESS_851208]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 37 [ZIP_CODE]  23. Carol H, Fan MM, Harasym TO, et al. Efficacy of CPX -351, (cytarabine:daunorubicin) liposome 
injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical 
Testing Program. Pediatr Blood Cancer. 2015 Jan;62(1):[ADDRESS_851209] -in-man study of CPX -351: a liposomal carrier containing 
cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011 Mar 10;29(8 ):979 -85. 
 
25. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX -351, a fixed 5:1 molar ratio of 
cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 
2014 May 22;123(21):3239 -46 
 
26. Cortes JE, Goldberg SL, Feldm an EJ, et al. Phase II, multicenter, randomized trial of CPX -351 
(cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first 
relapse AML. Cancer. 2015 Jan 15;121(2):234- 42 
 
27. Cheson BD, Bennett JM, Kopecky KJ, et al.  Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.  J Clin Oncol. 2003 Dec 15;21(24): 4642-
4649. 
 
28. De As tis E, Clavio M, Raiola AM, et al. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as 
bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. Ann Hematol. 2014 Dec;93(12):2011- 8. 
 29. SEER Cancer Registry, “Cancer Stat Fact s: 
Leukemia” https://seer.cancer.gov/statfacts/html/leuks.html
 
 
30. Pearce S., Brownsdon A., Fern L., Gibson F., Whelan J. & Lavender V . (2016) European Journal of 
Cancer Care. The perceptions of teenagers, young adults and professionals in the participation of bone cancer clinical trials. DOI: 10.1111/ecc.[ADDRESS_851210] congestive heart failure?  JAMA. 2005;294(15):1944- 1956.  
 
32. Cheson BD, Fisher RI, Barrington SF, Cavalli F , Schwartz LH, Zucca E. Recommendations for Initial 
Evaluation, Staging, and Response Assessment of Hodgkin and Non -Hodgkin Lymphoma: The Lugano 
Classification . J Clin Oncol 32:[ADDRESS_851211]  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 38 [ZIP_CODE]   
 
 
Appendix A     Response Criteria  
Complete remission (CR)a 
 Bone marrow blasts <5%; absence of blasts 
with Auer rods; absence of extramedullary 
disease; absolute neutrophil count >1.0 x 
109
/L (1000/μL); platelet count >100 x 109
/L 
(100,000/μL); independence from red cell 
transfusions  
CR with incomplete recovery (CRi)b 
 All CR criteria except for residual 
neutropenia (<1.0 x 109
/L 
[1000/μL]) or thrombocytopenia (<100 x 
109
/L [100,000/μL])  
Partial Response (PR)  Greater than 50% decrease in blasts, and/or 
decrease to less than 25% blasts with 
recovery of neutrophils ( >1.0 x 109
/L), and 
platelets   (>100 x 109
/L) 
Persistent Disease (PD)  Failure to achieve CR or CRi ; only includes 
patients surviving ≥7 days following 
completion of initial treatment, with evidence of persistent leukemia (blasts in peripheral blood, extramedullary leukemia, 
or persistence in the bone marrow)  
Relapsec 
 Bone marrow blasts ≥5%; or reappearance 
of blasts in the blood after achievement of a 
CR or CRi; or development of 
extramedullary disease  
a
Bone marrow assessment required to confirm CR. All criteria need to be fulfilled; marrow evaluation should 
be based  on a count of 200 nucleated cells in an aspi[INVESTIGATOR_241771]; if ambiguous, consider repeat exam 
after 5 to 7 days; flow cytometric evaluation may help to distinguish between persistent leukemia and regenerating normal marrow; a marrow biopsy should be performed in cases of dry tap, or if no spi[INVESTIGATOR_636644]; no minimum duration of response required.  
b
Bone marrow assessment required to confirm CRi. Some patients may not achieve complete hematologic 
recovery prior to initiation of consolidation. CRi cannot be declared earlier than Day [ADDRESS_851212] percentages (5 -10%), a repeat marrow s hould be performed to confirm relapse. 
Appearance of new dysplastic changes should be closely monitored for emerging relapse. In a patient who has been recently treated, dysplasia or a transient increase in blasts may reflect a chemotherapy effect and reco very of hematopoiesis.  
 
 
  
 
 
 
APPENDIX  
LIST  OF ABBREVIATIONS  Protocol Title: CPX -351 for Relapsed/Refractory ALL                                                                                           Protocol V. 3.0                                                              
Protocol #: [ZIP_CODE]                                                                                                                                                             11 Dec 2019   
 39 [ZIP_CODE]   
  
 
 
 
 
Appendix B  
ECOG Performance Status  
 
Grade  Description  
0 Normal activity. Fully active, able to carry on all pre -disease performance 
without restriction.  
1 Symptoms, but ambulatory. Restricted in physically strenuous activity, but 
ambulatory and able to carry out work of a light or sedentary nature (e.g., 
light housework, office work).  
2 In bed <50% of the time. Ambulatory and capable of all self -care, but 
unable to carry out any work activities. Up and about more than 50% of 
waking hours.  
3 In bed >50% of the time. Capable of only limited self -care, confined to bed 
or chair more than 50% of waking hours.  
4 100% bedridden. Completely disabled. Cannot carry on any self -care. 
Totally confined to bed or chair.  
5 Dead.  
* As published in Am. J. Clin. Oncol.:  Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, 
T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group. Am J Clin Oncol 5:649 -655, 1982. The Eastern Cooperative 
Oncology Group, Robert Comis M.D., Group Chair.  
 